{"gene":"KIT","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1987,"finding":"c-KIT encodes a 145 kDa transmembrane glycoprotein receptor tyrosine kinase structurally related to CSF-1 receptor and PDGF receptor, capable of self-phosphorylation on tyrosine residues; it was identified as a cell surface receptor for an unidentified ligand.","method":"cDNA cloning, peptide antibody identification, autophosphorylation assay in glioblastoma cells and transfected fibroblasts","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — original structural characterization with in vitro kinase assay, foundational paper","pmids":["2448137"],"is_preprint":false},{"year":1990,"finding":"c-KIT (encoded at the W locus) functions as a transmembrane receptor tyrosine kinase essential for development of hematopoietic, melanocyte, and germ cell lineages; W mutations impair kinase activity in mast cells from W/Wv mice.","method":"Genetic linkage of c-kit to W locus, kinase activity assay in W mutant mast cells, expression studies","journal":"Ciba Foundation symposium","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis plus functional kinase assay, replicated across multiple labs","pmids":["1690623"],"is_preprint":false},{"year":1990,"finding":"MGF (mast cell growth factor) is a ligand for c-KIT; 125I-labeled MGF cross-links to c-kit-expressing cells and the complex is immunoprecipitated with anti-c-kit antiserum, establishing MGF as the c-KIT ligand.","method":"Ligand purification, [3H]thymidine proliferation assay, 125I cross-linking, immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — direct receptor-ligand cross-linking and immunoprecipitation, highly cited foundational paper","pmids":["1698553"],"is_preprint":false},{"year":1990,"finding":"c-KIT protein is expressed on the surface of oocytes (primordial through full-grown) and spermatogonia, and has autophosphorylation activity in the ovary; its expression correlates with oocyte growth and gonial proliferation in germ cells.","method":"RNA blot analysis, in situ hybridization, indirect immunofluorescence, immune complex kinase assay","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1–2 — direct protein detection with autophosphorylation assay, replicated in multiple germ cell studies","pmids":["1712701"],"is_preprint":false},{"year":1992,"finding":"c-KIT signaling is required for the development of intestinal pacemaker cells (interstitial cells of Cajal); blockade with antagonistic anti-c-kit monoclonal antibody in neonatal mice and W/Wv mice results in defective autonomous gut pacing and lethal paralytic ileus.","method":"Anti-c-kit monoclonal antibody blockade in vivo, physiological analysis of gut motility in W/Wv mice","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — genetic and antibody loss-of-function with defined physiological readout, highly cited","pmids":["1283735"],"is_preprint":false},{"year":1992,"finding":"c-KIT cooperates with erythropoietin in erythroid progenitor proliferation; anti-c-Kit antibody inhibits proliferation but not differentiation during the early phase of erythropoietin response, and erythropoietin downregulates c-kit gene expression.","method":"Anti-c-Kit antibody inhibition in culture, erythroid progenitor colony assay, gene expression analysis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 — functional antibody blockade with defined proliferation readout, single lab","pmids":["1374312"],"is_preprint":false},{"year":1993,"finding":"Two point mutations in c-KIT coding sequence (Val560Gly and Asp816Val) in mast cell leukemia line HMC-1 cause ligand-independent constitutive autophosphorylation and activation of c-KIT; Asp816Val alone is sufficient for constitutive activation as demonstrated by site-directed mutagenesis in 293T cells.","method":"cDNA sequencing, site-directed mutagenesis, immune complex kinase assay, tyrosine phosphorylation detection in transfected cells","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis in heterologous cells, foundational mechanistic paper","pmids":["7691885"],"is_preprint":false},{"year":1994,"finding":"SCF binding to c-KIT induces receptor dimerization, kinase activation, and tyrosine phosphorylation of SH2-containing signaling molecules; downstream, Syp phosphatase associates with activated c-KIT via both its SH2 domains, becomes phosphorylated on tyrosine, and forms a complex with Grb2, linking c-KIT to Ras-Raf-MAP kinase activation.","method":"GST-SH2 domain pulldown, co-immunoprecipitation, in vitro binding assay, Ras activation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal pulldowns and Co-IP with in vitro binding confirmation, multiple orthogonal methods","pmids":["7523381"],"is_preprint":false},{"year":1994,"finding":"SCF/c-KIT interaction regulates oocyte growth in vitro; immune complex kinase assay demonstrates ovarian c-KIT autophosphorylation activity; anti-c-kit antibody (ACK2) severely inhibits oocyte growth in coculture.","method":"Immune complex kinase assay, oocyte culture with exogenous KL, ACK2 antibody blockade, Northern analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 1–2 — direct kinase assay plus antibody loss-of-function, multiple orthogonal methods","pmids":["7507447"],"is_preprint":false},{"year":1995,"finding":"A missense mutation in the KIT tyrosine kinase domain (Gly664Arg) causes piebaldism in humans, establishing that loss-of-function KIT mutations lead to melanocyte absence.","method":"Genetic linkage analysis, DNA sequencing of KIT gene in piebaldism family","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — segregation with phenotype in family plus sequencing, replicated across species","pmids":["1717985"],"is_preprint":false},{"year":1995,"finding":"A somatic Asp816Val point mutation in the catalytic domain of c-KIT causes ligand-independent autophosphorylation and is found in peripheral blood mononuclear cells of mastocytosis patients with associated hematologic disorders.","method":"RT-PCR, DNA sequencing of patient samples, correlation with ligand-independent autophosphorylation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — mutation identified in patient tissue, correlated with known constitutive activation mechanism","pmids":["7479840"],"is_preprint":false},{"year":1996,"finding":"Somatic activating c-KIT mutation (Asp816Val codon substitution) causes constitutive KIT receptor activation in mast cells of skin and spleen in urticaria pigmentosa/aggressive mastocytosis, establishing clonal and neoplastic nature of this disease.","method":"Tissue microdissection, DNA sequencing, demonstration of constitutive KIT activation","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — in situ mutation identified in purified neoplastic mast cells, first in situ demonstration","pmids":["8589724"],"is_preprint":false},{"year":1997,"finding":"SCF stimulation of mast cells via c-KIT induces differential release of IL-6, producing >100-fold more IL-6 than unstimulated cells, at concentrations causing little histamine, TNF-alpha, or leukotriene C4 release, demonstrating a selective signaling output of c-KIT.","method":"ELISA measurement of cytokine/mediator release from bone marrow-derived mast cells after SCF stimulation","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — defined cellular functional readout with dose-response, single lab","pmids":["9108382"],"is_preprint":false},{"year":1997,"finding":"HIV-1 Nef protein transactivates the c-kit promoter; overexpression of c-KIT in astrocytes induces apoptosis requiring the c-KIT tyrosine kinase domain, demonstrating a pro-apoptotic role for c-KIT in astrocytes.","method":"Promoter reporter assay, c-kit overexpression in astrocyte cell line, kinase domain mutagenesis, apoptosis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — promoter transactivation plus kinase domain requirement for apoptosis, single lab with multiple methods","pmids":["9108086"],"is_preprint":false},{"year":1998,"finding":"SCF stimulation of melanoma cells activates MAP kinase, which phosphorylates the transcription factor Microphthalmia (Mi) at a consensus serine, upregulating Mi-dependent transactivation of the tyrosinase gene promoter; this defines a KIT→MAPK→Mi signaling axis in melanocytes.","method":"SCF stimulation assay, MAP kinase activation, site-directed mutagenesis of Mi phosphorylation site, luciferase reporter assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical pathway delineation with mutagenesis and reporter assay, highly cited","pmids":["9440696"],"is_preprint":false},{"year":1998,"finding":"c-KIT signaling via MAPK phosphorylation of Mi recruits the transcriptional coactivator p300/CBP specifically to phospho-Mi, enhancing Mi transcriptional activity; phosphorylation does not alter Mi nuclear localization, DNA binding, or dimerization.","method":"Co-immunoprecipitation, reporter assay, phosphorylation-specific interaction assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with defined mechanistic consequence, replicated by Fisher lab","pmids":["9660747"],"is_preprint":false},{"year":1998,"finding":"SCF induces dose-dependent c-KIT receptor dimerization detectable by FRET within 3 minutes, followed by receptor capping and internalization; c-KIT is not recycled to the cell surface after internalization. Erythropoietin, but not thrombopoietin, also induces c-KIT dimerization and tyrosine phosphorylation, indicating Epo-c-Kit cross-talk.","method":"FRET with fluorochrome-conjugated anti-c-Kit antibodies, flow cytometry, confocal microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — FRET-based dimerization assay with kinetic analysis and confocal microscopy","pmids":["9446650"],"is_preprint":false},{"year":1998,"finding":"Gastrointestinal stromal tumors harbor gain-of-function mutations in c-KIT in the juxtamembrane region; mutant KIT proteins are constitutively activated without SCF; transfection of mutant c-kit cDNA causes malignant transformation of Ba/F3 cells; GISTs may originate from interstitial cells of Cajal.","method":"cDNA sequencing, stable transfection/transformation assay in Ba/F3 cells, immunohistochemistry","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — gain-of-function mutagenesis with transformation assay, most highly cited paper in field","pmids":["9438854"],"is_preprint":false},{"year":1998,"finding":"Familial GISTs harbor germline mutations in the KIT gene, establishing that KIT germline mutations predispose to GIST development.","method":"Germline DNA sequencing in familial GIST kindred","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — germline mutation identified with co-segregation with disease phenotype","pmids":["9697690"],"is_preprint":false},{"year":1999,"finding":"c-KIT juxtamembrane mutations in canine mastocytomas cause constitutive (ligand-independent) tyrosine phosphorylation of KIT, providing in situ evidence that the juxtamembrane region normally inhibits receptor kinase activity.","method":"cDNA sequencing from tumor tissue, tyrosine phosphorylation assay in mast cell lines","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 — in situ mutation with functional phosphorylation readout, multiple mutation types confirmed","pmids":["9989791"],"is_preprint":false},{"year":1999,"finding":"The Asp816Val activating mutation in c-KIT causes germ cell tumors; this mutation results in constitutively activated, tyrosine-phosphorylated KIT kinase in transfected cells.","method":"DNA sequencing of tumor tissue, cell transfection, tyrosine phosphorylation assay","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1 — transfection with constitutive activation demonstrated by phosphorylation assay","pmids":["10362788"],"is_preprint":false},{"year":1999,"finding":"c-KIT phosphatidylinositol 3-kinase (PI3K) activation is specifically required for spermatogonial differentiation but not for primordial germ cell maintenance; a point mutation abolishing PI3K binding causes complete male sterility due to failure of DNA synthesis in differentiating spermatogonia.","method":"PI3K-binding point mutation knock-in mouse, spermatogonia proliferation assay, DNA synthesis measurement","journal":"Journal of endocrinological investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with specific signaling pathway mutation and defined cellular phenotype","pmids":["11079457"],"is_preprint":false},{"year":1999,"finding":"A truncated c-kit product (tr-kit) expressed specifically in post-meiotic spermatids and mature sperm, when microinjected into mouse eggs, causes parthenogenetic activation, suggesting tr-kit plays a role in fertilization.","method":"Microinjection of tr-kit into mouse eggs, parthenogenetic activation assay","journal":"Journal of endocrinological investigation","confidence":"Medium","confidence_rationale":"Tier 2 — functional microinjection assay, single lab","pmids":["11079457"],"is_preprint":false},{"year":1999,"finding":"Src family kinase signaling is required for SCF-induced c-KIT internalization; PP1 (Src family kinase inhibitor) blocks capping and internalization of c-KIT; c-KIT can associate with clathrin independently of Src kinases; disruption of Lyn kinase expression also diminishes SCF-induced c-KIT internalization.","method":"PP1 inhibitor treatment, Lyn-deficient cell line, c-KIT trafficking assay, clathrin co-precipitation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — pharmacological and genetic inhibition with defined trafficking readout, multiple orthogonal approaches","pmids":["10477727"],"is_preprint":false},{"year":1999,"finding":"GNNK- isoform of c-KIT (lacking 4 amino acids in juxtamembrane extracellular region) shows more rapid and extensive tyrosine autophosphorylation, faster internalization, and stronger MAP kinase phosphorylation than GNNK+ isoform after ligand stimulation, resulting in superior transforming activity in NIH3T3 cells.","method":"Isoform expression in NIH3T3 cells, autophosphorylation assay, MAP kinase phosphorylation, colony formation, focus formation, nude mouse tumorigenicity","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — comparative isoform analysis with multiple functional assays and kinase measurements","pmids":["10523834"],"is_preprint":false},{"year":1999,"finding":"Activating mutations of c-KIT at Asp816 cause constitutive STAT3 and STAT1 activation; dominant negative STAT3 (but not STAT1) inhibits mutant c-Kit-mediated anchorage-independent growth and tumor formation, and constitutively active STAT3 restores transforming ability.","method":"Transfection of dominant negative STAT3/STAT1, anchorage-independent growth assay, in vivo tumor formation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — epistasis with dominant negatives and rescue experiment, in vitro and in vivo readouts","pmids":["11494148"],"is_preprint":false},{"year":2000,"finding":"c-KIT signaling triggers two phosphorylation events on Microphthalmia (Mi): MAPK/ERK targets Ser73 (upregulating transactivation and recruiting p300 coactivator) and p90 Rsk-1 targets Ser409; together these phosphorylations couple Mi transactivation to ubiquitin-dependent proteasomal degradation, creating short-lived Mi activation.","method":"Site-directed mutagenesis of Mi phosphorylation sites, reporter assay, co-immunoprecipitation with p300, ubiquitin-dependent degradation assay, protein stability measurement","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with multiple orthogonal readouts (transcription, degradation, coactivator recruitment), single rigorous paper","pmids":["10673502"],"is_preprint":false},{"year":2001,"finding":"The cytoplasmic domain of stem cell factor (SCF) contains a monomeric leucine-dependent basolateral targeting signal assisted by a cluster of acidic amino acids; this signal allows persistent cell surface exposure of SCF for c-KIT signaling; a mutated SCF (Mgf Sl17H) instead induces constitutive endocytosis via a lysosomal targeting motif.","method":"Site-directed mutagenesis of SCF cytoplasmic domain, polarized epithelial cell expression, cell surface biotinylation, endocytosis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with defined sorting assays, multiple orthogonal methods","pmids":["11152680"],"is_preprint":false},{"year":2002,"finding":"The SCL/TAL1 transcription factor complex (containing SCL, LMO2, GATA-1/2, E2A, Ldb-1) directly activates the c-kit promoter in hematopoietic cells by tethering via Sp1 zinc finger interaction at a GC-box; chromatin immunoprecipitation demonstrates SCL, E2A, and Sp1 co-occupy the c-kit promoter in vivo.","method":"Transient transfection reporter assay, co-immunoprecipitation of endogenous proteins, transgenic mouse model, chromatin immunoprecipitation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including in vivo ChIP and transgenic model","pmids":["12239153"],"is_preprint":false},{"year":2002,"finding":"Pharmacological dimerization of membrane-targeted c-KIT-FKBP12 fusion proteins using FK1012 or AP1510 is sufficient to activate c-KIT signaling and rescue Ba/F3 cells from IL-3 dependence, demonstrating that receptor dimerization alone is sufficient for c-KIT proliferative signaling.","method":"Chemical dimerizer-induced receptor dimerization, cell proliferation assay, IL-3 independence rescue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution of minimal dimerization requirement, clean functional readout","pmids":["9446649"],"is_preprint":false},{"year":2002,"finding":"KIT and PDGFRA mutations are alternative and mutually exclusive oncogenic mechanisms in GISTs; ~35% of GISTs lacking KIT mutations have activating PDGFRA mutations; tumors with either KIT or PDGFRA oncoproteins activate the same downstream signaling intermediates.","method":"Mutation sequencing, Western blot for downstream signaling, cytogenetic analysis","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — mutational analysis with downstream signaling comparison, highly cited","pmids":["12522257"],"is_preprint":false},{"year":2002,"finding":"The Asp816Val 'enzymatic site type' (EST) KIT mutation is resistant to imatinib (STI571) and SU9529 even at 10 µM, while juxtamembrane 'regulatory type' (RT) KIT mutations are sensitive; this classifies KIT mutations into two pharmacologically distinct categories.","method":"COS cell expression of wild-type and mutant KIT, kinase inhibition assay, HMC-1 subclone proliferation and apoptosis assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — kinase assay with isogenic cell lines differing only in mutation type, mechanistic framework established","pmids":["11861291"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of c-KIT in a fully active phosphorylated product complex reveals ordered kinase activation and phosphate-binding loops, providing molecular basis for c-KIT kinase transactivation.","method":"X-ray crystallography of c-KIT phosphorylated product complex","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation context","pmids":["12824176"],"is_preprint":false},{"year":2005,"finding":"The c-kit promoter region contains a DNA sequence that forms a stable intramolecular G-quadruplex structure under physiological conditions, as characterized by NMR, circular dichroism, and melting temperature measurements; this quadruplex may regulate c-kit transcription.","method":"NMR, circular dichroism, UV melting temperature analysis","journal":"Journal of the American Chemical Society","confidence":"High","confidence_rationale":"Tier 1 — multiple structural methods confirming quadruplex formation","pmids":["16045346"],"is_preprint":false},{"year":2006,"finding":"A second G-quadruplex-forming sequence (c-kit21) in the c-KIT promoter upstream of the transcription initiation site forms parallel quadruplexes under physiological conditions; mutational analysis reveals structural polymorphism; the sequence is highly conserved across human, mouse, rat, and chimpanzee.","method":"NMR, circular dichroism, UV spectroscopy, mutational analysis of quadruplex-forming sequence","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple structural methods with mutational dissection of the quadruplex","pmids":["16784237"],"is_preprint":false},{"year":2008,"finding":"Primary and secondary KIT mutation location determines sunitinib sensitivity; secondary KIT exon 13/14 mutations (ATP-binding pocket) confer sensitivity to sunitinib while exon 17/18 mutations (activation loop) confer resistance; biochemical profiling of specific mutants confirmed clinical findings.","method":"Tumor sequencing, biochemical profiling of KIT mutants in vitro, clinical outcome correlation in phase I/II trial","journal":"Journal of clinical oncology","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical profiling of specific mutants combined with clinical validation","pmids":["18955458"],"is_preprint":false},{"year":2010,"finding":"GATA2 and Sp1 co-occupy the c-kit promoter GC-box in mast cells and cooperatively transactivate c-kit; GATA2 is recruited to the c-kit promoter in a mast cell-specific manner by forming a complex with Sp1; siRNA knockdown of either factor reduces c-kit transcription and cell surface c-KIT expression.","method":"Reporter assay, EMSA, chromatin immunoprecipitation, re-ChIP, siRNA knockdown, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including in vivo ChIP and functional knockdown","pmids":["20833840"],"is_preprint":false},{"year":2017,"finding":"Engineered SCF partial agonist that impairs c-KIT dimerization truncates downstream signaling amplitude, resulting in biased activation of hematopoietic progenitors over mast cells; this demonstrates that signal amplitude (tuned by c-KIT dimerization efficiency) determines cell-type-specific biological outputs.","method":"SCF engineering, receptor dimerization assay, in vitro and in vivo cell activation assays, mouse models of anaphylaxis and hematopoietic expansion","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — mechanism-based receptor engineering with multiple in vitro and in vivo readouts","pmids":["28283060"],"is_preprint":false},{"year":2023,"finding":"Gαi1 and Gαi3 proteins associate with SCF-activated c-KIT, promote c-KIT endocytosis and adaptor protein binding, and are required for downstream Akt-mTOR and Erk activation; endothelial knockdown of Gαi1/3 suppresses SCF-induced retinal angiogenesis in vivo.","method":"Co-immunoprecipitation, Gαi1/3 siRNA/KO, dominant negative mutants, overexpression, HUVEC proliferation/migration/tube formation assay, in vivo AAV-mediated endothelial knockdown in retinal angiogenesis model","journal":"International journal of biological sciences","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus multiple genetic perturbations with in vivo validation","pmids":["37063428"],"is_preprint":false}],"current_model":"KIT is a type III receptor tyrosine kinase that, upon binding its ligand SCF/MGF, undergoes homodimerization (requiring sufficient dimerization for full signal amplitude), autophosphorylation, and activation of multiple downstream cascades including PI3K, MAPK/ERK, JAK/STAT3, and Src family kinases, with Gαi1/3 proteins facilitating c-KIT endocytosis and signal transduction; MAPK-mediated phosphorylation of the transcription factor Microphthalmia couples KIT signaling to melanocyte gene expression and proteasomal degradation; juxtamembrane mutations constitutively activate KIT (sensitive to imatinib), while activation-loop mutations (e.g., Asp816Val) confer imatinib resistance; the c-kit promoter contains conserved G-quadruplex structures and is transcriptionally regulated by SCL/TAL1 complex and GATA2/Sp1 in a cell-type-specific manner."},"narrative":{"teleology":[{"year":1987,"claim":"Identifying KIT as a transmembrane receptor tyrosine kinase with intrinsic autophosphorylation activity established the molecular framework for understanding how a proto-oncogene product could transduce extracellular signals.","evidence":"cDNA cloning and autophosphorylation assay in glioblastoma cells and transfected fibroblasts","pmids":["2448137"],"confidence":"High","gaps":["Ligand identity unknown at this point","Downstream signaling targets uncharacterized","No structural information on the kinase domain"]},{"year":1990,"claim":"Genetic mapping of c-kit to the W locus and identification of SCF/MGF as its ligand resolved a decades-old question about what receptor-ligand system governs hematopoietic, melanocyte, and germ cell development.","evidence":"Genetic linkage of c-kit to W locus with kinase activity assays in W mutant mast cells; 125I-MGF cross-linking and immunoprecipitation confirming ligand identity","pmids":["1690623","1698553","1712701"],"confidence":"High","gaps":["Mechanism of receptor activation upon ligand binding unknown","Downstream signaling cascades uncharacterized","Tissue-specific roles beyond hematopoiesis/melanocytes/germ cells not yet explored"]},{"year":1992,"claim":"Demonstrating that KIT signaling is required for interstitial cells of Cajal development and gut pacemaking revealed a non-hematopoietic physiological role and broadened the range of KIT-dependent cell lineages.","evidence":"Anti-c-kit antibody blockade in neonatal mice and W/Wv mutant gut motility analysis","pmids":["1283735"],"confidence":"High","gaps":["Molecular mechanism by which KIT supports ICC differentiation unknown","Whether KIT signals differently in ICC vs. mast cells not addressed"]},{"year":1993,"claim":"Discovery of constitutively activating KIT point mutations (Val560Gly and Asp816Val) in mast cell leukemia established that somatic gain-of-function mutations in KIT drive neoplasia, creating the conceptual basis for targeted therapy.","evidence":"cDNA sequencing of HMC-1 cells, site-directed mutagenesis with reconstitution in 293T cells showing ligand-independent autophosphorylation","pmids":["7691885"],"confidence":"High","gaps":["How juxtamembrane vs. activation-loop mutations differ mechanistically was unclear","Therapeutic targetability not yet tested"]},{"year":1994,"claim":"Delineation of the KIT→Syp/Grb2→Ras-Raf-MAPK signaling axis resolved how ligand-induced KIT dimerization couples to mitogenic signaling.","evidence":"GST-SH2 pulldown, co-immunoprecipitation, and Ras activation assay after SCF stimulation","pmids":["7523381"],"confidence":"High","gaps":["PI3K and STAT pathways downstream of KIT not yet characterized","Signaling specificity between KIT isoforms unknown"]},{"year":1995,"claim":"Identification of KIT loss-of-function mutations in piebaldism families and Asp816Val in mastocytosis patients established a clinical mutation spectrum spanning both loss- and gain-of-function phenotypes.","evidence":"Genetic linkage and DNA sequencing in piebaldism kindred; RT-PCR sequencing of patient blood in mastocytosis","pmids":["1717985","7479840"],"confidence":"High","gaps":["Genotype-phenotype correlation for different KIT domains incomplete","Mechanism by which loss-of-function selectively affects melanocytes unclear"]},{"year":1998,"claim":"Simultaneous discoveries that KIT→MAPK phosphorylates MITF to recruit p300/CBP for melanocyte gene transactivation, and that juxtamembrane KIT mutations drive GISTs, connected KIT signaling to both normal transcriptional programming and solid tumor oncogenesis.","evidence":"SCF stimulation with MAPK-dependent MITF phosphorylation and reporter assay; cDNA sequencing of GISTs with Ba/F3 transformation assay; germline KIT mutation in familial GIST","pmids":["9440696","9660747","9438854","9697690"],"confidence":"High","gaps":["How MITF phosphorylation is coupled to its proteasomal degradation unknown","Structural basis for juxtamembrane autoinhibition not resolved","Whether GIST signaling differs from normal ICC signaling unclear"]},{"year":1999,"claim":"Functional dissection of KIT downstream pathways revealed that PI3K binding is specifically required for spermatogonial differentiation, Src kinases control KIT internalization, GNNK- isoform has enhanced signaling, and Asp816Val activates STAT3 for transformation — establishing pathway-selective and isoform-specific outputs.","evidence":"PI3K-binding knock-in mouse with male sterility; PP1 inhibition and Lyn-deficient cells blocking KIT internalization; GNNK± isoform comparison in NIH3T3; dominant-negative STAT3 blocking Asp816Val transformation","pmids":["11079457","10477727","10523834","11494148"],"confidence":"High","gaps":["Integration of PI3K, STAT3, MAPK signals into a unified model lacking","How isoform expression is regulated in different tissues unknown","Whether STAT3 is required for all gain-of-function mutants unclear"]},{"year":2000,"claim":"Showing that MAPK and Rsk-1 dual phosphorylation of MITF couples transcriptional activation to ubiquitin-dependent degradation resolved how KIT produces short-lived bursts of melanocyte gene expression.","evidence":"Site-directed mutagenesis of MITF Ser73 and Ser409, reporter assay, p300 co-IP, and proteasomal degradation assay","pmids":["10673502"],"confidence":"High","gaps":["E3 ligase responsible for phospho-MITF ubiquitination unidentified","Whether this coupling mechanism operates in non-melanocyte KIT-expressing cells unknown"]},{"year":2002,"claim":"Pharmacological classification of KIT mutations into imatinib-sensitive juxtamembrane and imatinib-resistant activation-loop categories, together with forced-dimerization experiments proving dimerization sufficiency, provided the mechanistic logic for mutation-specific targeted therapy.","evidence":"COS cell kinase inhibition assays comparing juxtamembrane vs. Asp816Val mutants with imatinib/SU9529; FKBP12-based chemical dimerization rescue of Ba/F3 cells","pmids":["11861291","9446649","12522257"],"confidence":"High","gaps":["Structural basis for imatinib resistance at Asp816 not solved","Secondary resistance mechanisms not addressed"]},{"year":2003,"claim":"The crystal structure of the phosphorylated KIT kinase domain in a product complex provided the first atomic-resolution view of the active conformation, explaining transactivation geometry and informing inhibitor design.","evidence":"X-ray crystallography of phosphorylated c-KIT kinase domain","pmids":["12824176"],"confidence":"High","gaps":["Structure of full-length KIT or KIT–SCF complex unavailable","How Asp816Val alters the activation loop conformation structurally unresolved at this time"]},{"year":2005,"claim":"Discovery of conserved G-quadruplex structures in the KIT promoter introduced a novel layer of transcriptional regulation potentially targetable by small molecules.","evidence":"NMR, circular dichroism, and UV melting analysis of two G-quadruplex-forming sequences in the c-kit promoter","pmids":["16045346","16784237"],"confidence":"High","gaps":["Functional consequence of quadruplex formation on KIT transcription not demonstrated in cells","No quadruplex-binding compounds tested for transcriptional effect"]},{"year":2010,"claim":"Identifying GATA2/Sp1 cooperative transactivation of the c-kit promoter in mast cells, complementing the earlier SCL/TAL1 complex in hematopoietic progenitors, revealed cell-type-specific transcriptional control of KIT expression.","evidence":"ChIP, re-ChIP, EMSA, and siRNA knockdown in mast cells showing GATA2–Sp1 co-occupancy","pmids":["20833840","12239153"],"confidence":"High","gaps":["How chromatin context and G-quadruplexes integrate with transcription factor binding unknown","Transcriptional regulation of KIT in melanocytes and ICC not comparably dissected"]},{"year":2017,"claim":"Engineered SCF partial agonists that reduce KIT dimerization efficiency demonstrated that signal amplitude, not just signal quality, determines cell-type-selective biological outcomes — separating hematopoietic expansion from mast cell activation.","evidence":"SCF engineering with in vitro dimerization assays, hematopoietic progenitor and mast cell activation assays, and mouse anaphylaxis/hematopoiesis models","pmids":["28283060"],"confidence":"High","gaps":["Molecular basis for differential sensitivity thresholds in progenitors vs. mast cells unresolved","Clinical translatability of partial agonist approach not established"]},{"year":2023,"claim":"Discovery that Gαi1/3 proteins associate with activated KIT to promote its endocytosis and sustain Akt-mTOR/Erk signaling added a heterotrimeric G protein component to KIT signal transduction previously considered exclusively tyrosine-kinase-driven.","evidence":"Co-IP, Gαi1/3 siRNA/KO in HUVECs, dominant-negative mutants, and AAV-mediated endothelial knockdown in retinal angiogenesis model","pmids":["37063428"],"confidence":"High","gaps":["Whether Gαi coupling operates in hematopoietic or mast cell contexts unknown","Structural basis for Gαi–KIT interaction uncharacterized","Role of Gαi in mutant KIT signaling not tested"]},{"year":null,"claim":"Key unresolved questions include the full-length KIT–SCF complex structure at atomic resolution, the E3 ligase responsible for phospho-MITF degradation downstream of KIT, how G-quadruplex structures functionally regulate KIT transcription in vivo, and whether Gαi coupling modulates KIT signaling in the mast cell and hematopoietic contexts where KIT is most physiologically important.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length KIT–SCF ectodomain complex structure","E3 ligase for MITF downstream of KIT unidentified","In vivo functional role of promoter G-quadruplexes not demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,6,7,24,32]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,7,16,37]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,6,32]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,3,16,23,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,14,15,21,25,26,37,38]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,4,9,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,10,11,17,20,30,31,35]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,12]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[28,33,34,36]}],"complexes":[],"partners":["KITLG","MITF","PTPN11","GRB2","LYN","STAT3","GNAI1","GNAI3"],"other_free_text":[]},"mechanistic_narrative":"KIT is a type III receptor tyrosine kinase that, upon binding its ligand stem cell factor (SCF/MGF), undergoes rapid homodimerization, autophosphorylation, and activation of PI3K, MAPK/ERK, JAK/STAT3, and Src family kinase cascades to govern the development, proliferation, and survival of hematopoietic progenitors, melanocytes, germ cells, interstitial cells of Cajal, and mast cells [PMID:1698553, PMID:1690623, PMID:1283735, PMID:7507447]. SCF-induced KIT dimerization efficiency controls signaling amplitude and cell-type-selective biological output, with engineered partial agonists demonstrating that reduced dimerization biases activation toward hematopoietic progenitors over mast cells [PMID:28283060, PMID:9446650]. Downstream, MAPK phosphorylates the transcription factor Microphthalmia (MITF) to recruit p300/CBP and couple transactivation of melanocyte genes to ubiquitin-dependent proteasomal degradation of MITF, while Gαi1/3 proteins facilitate KIT endocytosis and Akt-mTOR/Erk signaling [PMID:9440696, PMID:10673502, PMID:37063428]. Gain-of-function KIT mutations in the juxtamembrane domain cause gastrointestinal stromal tumors (GISTs) and are imatinib-sensitive, whereas activation-loop mutations (notably Asp816Val) constitutively activate STAT3-dependent transformation and confer imatinib resistance, and germline loss-of-function mutations cause piebaldism [PMID:9438854, PMID:11861291, PMID:1717985]."},"prefetch_data":{"uniprot":{"accession":"P10721","full_name":"Mast/stem cell growth factor receptor Kit","aliases":["Piebald trait protein","PBT","Proto-oncogene c-Kit","Tyrosine-protein kinase Kit","p145 c-kit","v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog"],"length_aa":976,"mass_kda":109.9,"function":"Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P10721/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KIT","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KIT","total_profiled":1310},"omim":[{"mim_id":"621391","title":"XK-RELATED PROTEIN 5; XKR5","url":"https://www.omim.org/entry/621391"},{"mim_id":"621205","title":"MICRO RNA 129-2; MIR129-2","url":"https://www.omim.org/entry/621205"},{"mim_id":"621204","title":"MICRO RNA 129-1; MIR129-1","url":"https://www.omim.org/entry/621204"},{"mim_id":"619947","title":"WAARDENBURG SYNDROME, TYPE 2F; WS2F","url":"https://www.omim.org/entry/619947"},{"mim_id":"619233","title":"STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 14; SAMD14","url":"https://www.omim.org/entry/619233"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"breast","ntpm":79.2}],"url":"https://www.proteinatlas.org/search/KIT"},"hgnc":{"alias_symbol":["CD117","SCFR","C-Kit"],"prev_symbol":["PBT"]},"alphafold":{"accession":"P10721","domains":[{"cath_id":"2.60.40.10","chopping":"39-113","consensus_level":"medium","plddt":94.2704,"start":39,"end":113},{"cath_id":"2.60.40.10","chopping":"126-206","consensus_level":"medium","plddt":94.1862,"start":126,"end":206},{"cath_id":"2.60.40.10","chopping":"214-309","consensus_level":"high","plddt":92.583,"start":214,"end":309},{"cath_id":"2.60.40.10","chopping":"312-508","consensus_level":"medium","plddt":83.1457,"start":312,"end":508},{"cath_id":"1.10.510.10","chopping":"559-681_764-941","consensus_level":"medium","plddt":84.7031,"start":559,"end":941}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10721","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10721-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10721-F1-predicted_aligned_error_v6.png","plddt_mean":78.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KIT","jax_strain_url":"https://www.jax.org/strain/search?query=KIT"},"sequence":{"accession":"P10721","fasta_url":"https://rest.uniprot.org/uniprotkb/P10721.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10721/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10721"}},"corpus_meta":[{"pmid":"1698553","id":"PMC_1698553","title":"Identification of a ligand for the c-kit proto-oncogene.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1698553","citation_count":990,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1283735","id":"PMC_1283735","title":"Requirement of c-kit for development of intestinal pacemaker system.","date":"1992","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1283735","citation_count":606,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9440696","id":"PMC_9440696","title":"MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9440696","citation_count":529,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16045346","id":"PMC_16045346","title":"Putative DNA quadruplex formation within the human c-kit oncogene.","date":"2005","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/16045346","citation_count":456,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16082245","id":"PMC_16082245","title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation.","date":"2005","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/16082245","citation_count":447,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1712701","id":"PMC_1712701","title":"Gonadal expression of c-kit encoded at the W locus of the mouse.","date":"1990","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1712701","citation_count":440,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11048809","id":"PMC_11048809","title":"Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).","date":"2000","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/11048809","citation_count":434,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10673502","id":"PMC_10673502","title":"c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10673502","citation_count":420,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10582339","id":"PMC_10582339","title":"Early signaling pathways activated by c-Kit in hematopoietic cells.","date":"1999","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10582339","citation_count":305,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11865845","id":"PMC_11865845","title":"Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.","date":"2002","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11865845","citation_count":251,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16483568","id":"PMC_16483568","title":"Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.","date":"2006","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16483568","citation_count":208,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7507447","id":"PMC_7507447","title":"The ligand of the c-kit receptor promotes oocyte growth.","date":"1994","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7507447","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12824176","id":"PMC_12824176","title":"Structure of a c-kit product complex reveals the basis for kinase transactivation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12824176","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10582791","id":"PMC_10582791","title":"Stem cell factor/c-kit system in spermatogenesis.","date":"1999","source":"Human reproduction update","url":"https://pubmed.ncbi.nlm.nih.gov/10582791","citation_count":171,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9660747","id":"PMC_9660747","title":"Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9660747","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1371338","id":"PMC_1371338","title":"Loss of c-kit expression in cultured melanoma cells.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1371338","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16481408","id":"PMC_16481408","title":"Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis.","date":"2006","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16481408","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15095270","id":"PMC_15095270","title":"Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15095270","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12239153","id":"PMC_12239153","title":"The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12239153","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7523381","id":"PMC_7523381","title":"The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7523381","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11079457","id":"PMC_11079457","title":"Role of c-kit in mammalian spermatogenesis.","date":"2000","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11079457","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9989791","id":"PMC_9989791","title":"Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9989791","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23127174","id":"PMC_23127174","title":"Therapeutic targeting of c-KIT in cancer.","date":"2012","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/23127174","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7513517","id":"PMC_7513517","title":"The riddle of the mast cell: kit(CD117)-ligand as the missing link?","date":"1994","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/7513517","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16002927","id":"PMC_16002927","title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.","date":"2005","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/16002927","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15780908","id":"PMC_15780908","title":"Role of c-Kit and erythropoietin receptor in erythropoiesis.","date":"2005","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15780908","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9711908","id":"PMC_9711908","title":"Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis.","date":"1998","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9711908","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29518044","id":"PMC_29518044","title":"CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.","date":"2018","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/29518044","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10670573","id":"PMC_10670573","title":"c-Kit and c-kit mutations in mastocytosis and other hematological diseases.","date":"2000","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10670573","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7531500","id":"PMC_7531500","title":"Steel factor and c-kit protooncogene: genetic lessons in signal transduction.","date":"1994","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/7531500","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8555071","id":"PMC_8555071","title":"c-kit point mutation of extracellular domain in patients with myeloproliferative disorders.","date":"1995","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/8555071","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9108382","id":"PMC_9108382","title":"Differential release of mast cell interleukin-6 via c-kit.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9108382","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14515175","id":"PMC_14515175","title":"Role of c-kit/Kit ligand signaling in regulating vasculogenesis.","date":"2003","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/14515175","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11914628","id":"PMC_11914628","title":"Expression of KIT (CD117) in angiomyolipoma.","date":"2002","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11914628","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8978830","id":"PMC_8978830","title":"HEMCAM, an adhesion molecule expressed by c-kit+ hemopoietic progenitors.","date":"1996","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8978830","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10523834","id":"PMC_10523834","title":"Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10523834","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23328669","id":"PMC_23328669","title":"Mast cells rescue implantation defects caused by c-kit deficiency.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23328669","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23944364","id":"PMC_23944364","title":"C-KIT signaling in cancer treatment.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/23944364","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15044257","id":"PMC_15044257","title":"Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15044257","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15036937","id":"PMC_15036937","title":"Targeting c-Kit mutations: basic science to novel therapies.","date":"2004","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/15036937","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20833650","id":"PMC_20833650","title":"C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment.","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20833650","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10477727","id":"PMC_10477727","title":"Signaling via Src family kinases is required for normal internalization of the receptor c-Kit.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10477727","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7536131","id":"PMC_7536131","title":"Transformation of thyroid epithelium is associated with loss of c-kit receptor.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7536131","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1690623","id":"PMC_1690623","title":"The mouse W/c-kit locus.","date":"1990","source":"Ciba Foundation symposium","url":"https://pubmed.ncbi.nlm.nih.gov/1690623","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34606974","id":"PMC_34606974","title":"A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors.","date":"2021","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34606974","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20425418","id":"PMC_20425418","title":"Clinical implications of c-Kit mutations in acute myelogenous leukemia.","date":"2009","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/20425418","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11494148","id":"PMC_11494148","title":"STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11494148","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9407735","id":"PMC_9407735","title":"Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias.","date":"1997","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/9407735","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28283060","id":"PMC_28283060","title":"Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28283060","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12893208","id":"PMC_12893208","title":"The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.","date":"2003","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12893208","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11756760","id":"PMC_11756760","title":"CD117 (KIT): a diverse protein with selective applications in surgical pathology.","date":"2002","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11756760","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15861301","id":"PMC_15861301","title":"The proto-oncogene C-KIT maps to canid B-chromosomes.","date":"2005","source":"Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology","url":"https://pubmed.ncbi.nlm.nih.gov/15861301","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31275242","id":"PMC_31275242","title":"Role of c-Kit in Myocardial Regeneration and Aging.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31275242","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25452341","id":"PMC_25452341","title":"Flexibility and structural conservation in a c-KIT G-quadruplex.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25452341","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17145623","id":"PMC_17145623","title":"Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS.","date":"2007","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17145623","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20146711","id":"PMC_20146711","title":"Signaling of c-kit in dendritic cells influences adaptive immunity.","date":"2010","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20146711","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15086281","id":"PMC_15086281","title":"The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature.","date":"2004","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15086281","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9108086","id":"PMC_9108086","title":"Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9108086","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7520225","id":"PMC_7520225","title":"Expression of c-kit ligand in human keratinocytes.","date":"1994","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/7520225","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20833840","id":"PMC_20833840","title":"GATA2 and Sp1 positively regulate the c-kit promoter in mast cells.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20833840","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11152680","id":"PMC_11152680","title":"Stem cell factor presentation to c-Kit. Identification of a basolateral targeting domain.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11152680","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8914068","id":"PMC_8914068","title":"Gonocytes in testes of neonatal rats express the c-kit gene.","date":"1996","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/8914068","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26245347","id":"PMC_26245347","title":"Extended molecular dynamics of a c-kit promoter quadruplex.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26245347","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9168438","id":"PMC_9168438","title":"c-kit Point mutation in patients with myeloproliferative disorders.","date":"1997","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9168438","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18977066","id":"PMC_18977066","title":"RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18977066","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12457280","id":"PMC_12457280","title":"Simultaneous targeted alteration of the tyrosinase and c-kit genes by single-stranded oligonucleotides.","date":"2002","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12457280","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8891342","id":"PMC_8891342","title":"Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements.","date":"1996","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/8891342","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9446650","id":"PMC_9446650","title":"Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9446650","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17191042","id":"PMC_17191042","title":"C-kit Asp-816-Val mutation analysis in patients with mastocytosis.","date":"2007","source":"Dermatology (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/17191042","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10354021","id":"PMC_10354021","title":"Lack of c-kit mutation in familial urticaria pigmentosa.","date":"1999","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10354021","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9446649","id":"PMC_9446649","title":"Stimulating cell proliferation through the pharmacologic activation of c-kit.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9446649","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9817449","id":"PMC_9817449","title":"Brain mast cells lack the c-kit receptor: immunocytochemical evidence.","date":"1998","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/9817449","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16236162","id":"PMC_16236162","title":"The role of c-kit and imatinib mesylate in uveal melanoma.","date":"2005","source":"Journal of carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16236162","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1379619","id":"PMC_1379619","title":"The c-kit proto-oncogene in normal and malignant human hematopoiesis.","date":"1992","source":"International journal of cell cloning","url":"https://pubmed.ncbi.nlm.nih.gov/1379619","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22789565","id":"PMC_22789565","title":"Targeting c-kit in the therapy of mast cell disorders: current update.","date":"2012","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22789565","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17607922","id":"PMC_17607922","title":"C-kit, GIST, and imatinib.","date":"2007","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17607922","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29636378","id":"PMC_29636378","title":"Cardiac c-Kit Biology Revealed by Inducible Transgenesis.","date":"2018","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/29636378","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26449497","id":"PMC_26449497","title":"CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma.","date":"2015","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26449497","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25594040","id":"PMC_25594040","title":"Resistance to c-Kit inhibitors in melanoma: insights for future therapies.","date":"2014","source":"Oncoscience","url":"https://pubmed.ncbi.nlm.nih.gov/25594040","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25621158","id":"PMC_25621158","title":"Imatinib in pulmonary arterial hypertension: c-Kit inhibition.","date":"2014","source":"Pulmonary circulation","url":"https://pubmed.ncbi.nlm.nih.gov/25621158","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16131001","id":"PMC_16131001","title":"A study of mutations in the c-kit gene of 32 dogs with mastocytoma.","date":"2005","source":"Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16131001","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33446896","id":"PMC_33446896","title":"CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33446896","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7536510","id":"PMC_7536510","title":"Expression of c-kit receptor (CD117) and CD34 in leukemic cells.","date":"1995","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/7536510","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12453327","id":"PMC_12453327","title":"Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma.","date":"2002","source":"Clinical colorectal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12453327","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10492068","id":"PMC_10492068","title":"Effects of mutant c-Kit in early myeloid cells.","date":"1999","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/10492068","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15617841","id":"PMC_15617841","title":"Expression of c-kit protooncogene in human hepatocellular carcinoma.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15617841","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9207448","id":"PMC_9207448","title":"Downregulation of c-kit expression in human endothelial cells by inflammatory stimuli.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9207448","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28627370","id":"PMC_28627370","title":"Chasing c-Kit through the heart: Taking a broader view.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28627370","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12649669","id":"PMC_12649669","title":"C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance.","date":"2003","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/12649669","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12610358","id":"PMC_12610358","title":"The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining.","date":"2003","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/12610358","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33603771","id":"PMC_33603771","title":"C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33603771","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15589603","id":"PMC_15589603","title":"Expression of c-kit in uterine carcinosarcoma.","date":"2005","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15589603","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16373964","id":"PMC_16373964","title":"Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.","date":"2005","source":"Cellular oncology : the official journal of the International Society for Cellular Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16373964","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37063428","id":"PMC_37063428","title":"SCF/c-Kit-activated signaling and angiogenesis require Gαi1 and Gαi3.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37063428","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11987084","id":"PMC_11987084","title":"Abnormalities of C-Kit-positive cellular network in isolated hypoganglionosis.","date":"2002","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/11987084","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23709168","id":"PMC_23709168","title":"Inhibition of c-Kit signaling by diosmetin isolated from Chrysanthemum morifolium.","date":"2013","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/23709168","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30459357","id":"PMC_30459357","title":"miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30459357","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1374312","id":"PMC_1374312","title":"Combined action of c-kit and erythropoietin on erythroid progenitor cells.","date":"1992","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1374312","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25451758","id":"PMC_25451758","title":"Hormonal regulation of c-KIT receptor and its ligand: implications for human infertility?","date":"2014","source":"Progress in histochemistry and cytochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25451758","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29747481","id":"PMC_29747481","title":"Carbazole Derivatives' Binding to c-KIT G-Quadruplex DNA.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29747481","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9438854","id":"PMC_9438854","title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9438854","citation_count":3475,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12522257","id":"PMC_12522257","title":"PDGFRA activating mutations in gastrointestinal stromal tumors.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12522257","citation_count":1874,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2448137","id":"PMC_2448137","title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.","date":"1987","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2448137","citation_count":1534,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16365291","id":"PMC_16365291","title":"The role of microRNA genes in papillary thyroid carcinoma.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16365291","citation_count":980,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7479840","id":"PMC_7479840","title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7479840","citation_count":742,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7691885","id":"PMC_7691885","title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.","date":"1993","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/7691885","citation_count":704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18955458","id":"PMC_18955458","title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18955458","citation_count":612,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16076867","id":"PMC_16076867","title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16076867","citation_count":562,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21690468","id":"PMC_21690468","title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.","date":"2011","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21690468","citation_count":514,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18980976","id":"PMC_18980976","title":"KIT gene mutations and copy number in melanoma subtypes.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18980976","citation_count":513,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8589724","id":"PMC_8589724","title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8589724","citation_count":509,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18955451","id":"PMC_18955451","title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18955451","citation_count":471,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9990072","id":"PMC_9990072","title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9990072","citation_count":456,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23775962","id":"PMC_23775962","title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.","date":"2013","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23775962","citation_count":453,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9697690","id":"PMC_9697690","title":"Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9697690","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15685537","id":"PMC_15685537","title":"Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.","date":"2005","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15685537","citation_count":413,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20139978","id":"PMC_20139978","title":"Genome-wide association study of hematological and biochemical traits in a Japanese population.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20139978","citation_count":406,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16741248","id":"PMC_16741248","title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16741248","citation_count":400,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19167335","id":"PMC_19167335","title":"Large-scale structural analysis of the classical human protein tyrosine phosphatome.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19167335","citation_count":393,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11861291","id":"PMC_11861291","title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11861291","citation_count":371,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10362788","id":"PMC_10362788","title":"Activating c-kit gene mutations in human germ cell tumors.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10362788","citation_count":356,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16784237","id":"PMC_16784237","title":"A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16784237","citation_count":332,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19789626","id":"PMC_19789626","title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19789626","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18312355","id":"PMC_18312355","title":"Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.","date":"2008","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18312355","citation_count":319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1717985","id":"PMC_1717985","title":"Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1717985","citation_count":307,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16551858","id":"PMC_16551858","title":"Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16551858","citation_count":304,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44334,"output_tokens":5771,"usd":0.109784},"stage2":{"model":"claude-opus-4-6","input_tokens":9418,"output_tokens":3419,"usd":0.198848},"total_usd":0.698939,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":58840,"output_tokens":8123,"usd":0.149182},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12225,"output_tokens":3985,"usd":0.241125}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"MGF (mast cell growth factor / SCF) was identified as a direct ligand for the c-Kit receptor by cross-linking 125I-labeled MGF to c-Kit-expressing cells followed by immunoprecipitation with anti-c-Kit antiserum, establishing the SCF–KIT receptor-ligand pair.\",\n      \"method\": \"Radiolabeled ligand cross-linking and immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical binding assay with immunoprecipitation, foundational paper with 990 citations\",\n      \"pmids\": [\"1698553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The c-Kit receptor tyrosine kinase encoded at the W locus is required cell-autonomously for development of erythrocytes, melanocytes, germ cells, and mast cells; tyrosine kinase activity associated with c-Kit protein is functionally impaired in mast cells from W/Wv mutant mice.\",\n      \"method\": \"Genetic epistasis in mouse W mutants; kinase activity assay in mutant mast cells\",\n      \"journal\": \"Ciba Foundation symposium\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function genetics with defined cellular phenotypes replicated across multiple lineages\",\n      \"pmids\": [\"1690623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"c-Kit signaling is required for development of intestinal pacemaker cells (interstitial cells of Cajal); antagonistic anti-c-Kit monoclonal antibody treatment postnally abolishes autonomous pacing of gut contraction, producing paralytic ileus.\",\n      \"method\": \"In vivo antibody blockade of c-Kit; physiological analysis of gut motility\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antibody-mediated loss-of-function with specific physiological phenotype, corroborated by W mutant mice\",\n      \"pmids\": [\"1283735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"c-Kit antibody inhibits stromal cell-dependent erythroid progenitor colony formation and early proliferation driven by erythropoietin; erythropoietin downregulates c-kit gene expression within 6 hours, revealing cross-talk between EPO and c-Kit signaling.\",\n      \"method\": \"Antibody inhibition assay in erythroid progenitor cultures; Northern blot for c-kit expression\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional antibody block with defined cellular readout, single study\",\n      \"pmids\": [\"1374312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SCF (KL) directly promotes oocyte growth through c-Kit receptor; immune complex kinase assay demonstrated autophosphorylation activity of ovarian c-Kit; ACK2 anti-c-Kit antibody blocked oocyte growth in vitro; genistein inhibited c-Kit-dependent growth.\",\n      \"method\": \"Immune complex kinase assay; antibody blockade; tyrosine kinase inhibitor treatment in follicle culture\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — kinase activity assay plus functional antibody blockade with defined phenotype\",\n      \"pmids\": [\"7507447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Upon SCF binding, the c-Kit receptor undergoes dimerization, kinase activation, and tyrosine phosphorylation of cytoplasmic SH2-domain-containing proteins, initiating downstream signaling cascades.\",\n      \"method\": \"Biochemical and genetic analysis of SCF/c-Kit signaling in mice; structure-function review synthesizing experimental data\",\n      \"journal\": \"Critical reviews in oncogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical and genetic methods, replicated across labs\",\n      \"pmids\": [\"7531500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SHP-2 (Syp) phosphotyrosine phosphatase associates with activated c-Kit receptor via both its N-terminal and C-terminal SH2 domains after SCF stimulation; tyrosine-phosphorylated SHP-2 then complexes with Grb2, linking c-Kit to Ras/Raf activation.\",\n      \"method\": \"Co-immunoprecipitation; GST fusion protein pulldown; in vitro binding assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and in vitro GST pulldown, multiple interaction partners defined\",\n      \"pmids\": [\"7523381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SCF/c-Kit signaling activates MAP kinase, which phosphorylates the melanocyte transcription factor Microphthalmia (Mi/MITF) at a consensus serine, upregulating Mi-dependent transactivation of the tyrosinase pigmentation gene promoter.\",\n      \"method\": \"MAP kinase phosphorylation assay; transcriptional reporter assay in melanoma cells; mutational analysis of Mi phosphorylation site\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — kinase assay, mutagenesis, reporter assay, replicated; 529 citations\",\n      \"pmids\": [\"9440696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MAP kinase-phosphorylated Microphthalmia (Mi) selectively recruits the transcriptional coactivator p300/CBP; p300/CBP coactivates Mi transcriptional activity in a phosphorylation-dependent manner; phosphorylation does not alter Mi nuclear localization, DNA binding, or dimerization.\",\n      \"method\": \"Co-immunoprecipitation; transcriptional reporter assay; phosphorylation-site mutagenesis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP with mutagenesis and reporter assay, mechanistically detailed\",\n      \"pmids\": [\"9660747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SCF induces c-Kit receptor dimerization in a dose-dependent manner detectable within 3 minutes; dimerization is followed by receptor capping and internalization; erythropoietin (but not thrombopoietin) also stimulates c-Kit dimerization, indicating cross-talk between EPO and c-Kit receptors.\",\n      \"method\": \"Fluorescence resonance energy transfer (FRET) on intact cells; confocal microscopy; flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biophysical measurement of receptor dimerization in real time with FRET and confocal microscopy\",\n      \"pmids\": [\"9446650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Pharmacologic dimerization of a membrane-targeted c-Kit cytoplasmic domain fusion (via FKBP12 dimerizer) is sufficient to trigger proliferative signaling, demonstrating that receptor dimerization alone suffices for c-Kit signaling.\",\n      \"method\": \"Chemical dimerization of chimeric c-Kit/FKBP12 fusion protein; cell proliferation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reconstitution with engineered dimerizer, single study\",\n      \"pmids\": [\"9446649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"c-Kit juxtamembrane mutations cause constitutive, ligand-independent tyrosine phosphorylation of KIT, demonstrating an inhibitory role for the juxtamembrane region in controlling kinase activity.\",\n      \"method\": \"Sequencing of c-KIT juxtamembrane region from tumors and cell lines; tyrosine phosphorylation assay\",\n      \"journal\": \"Journal of Investigative Dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical measurement of constitutive phosphorylation from in situ mutations\",\n      \"pmids\": [\"9989791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GNNK− isoform of c-KIT (lacking four extracellular juxtamembrane amino acids) shows more rapid and extensive tyrosine autophosphorylation, faster internalization, greater MAP kinase phosphorylation, and stronger transforming activity compared to GNNK+ isoform, demonstrating isoform-specific differences in signaling.\",\n      \"method\": \"NIH3T3 transformation assay; saturation binding; receptor phosphorylation and internalization assays; MAP kinase phosphorylation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal assays comparing isoform-specific signaling in a single rigorous study\",\n      \"pmids\": [\"10523834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SCF/c-Kit activates downstream signaling through multiple pathways including PI3-kinase, Src family members, JAK/STAT, and Ras-Raf-MAP kinase cascades in hematopoietic cells.\",\n      \"method\": \"Structure-function studies using signaling pathway inhibitors and mutant receptors in hematopoietic cell lines\",\n      \"journal\": \"International Journal of Biochemistry and Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of multiple structure-function studies with defined signaling readouts\",\n      \"pmids\": [\"10582339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Src family kinases are required for SCF-induced capping and internalization of c-Kit; PP1 (Src inhibitor) blocks internalization; c-Kit still associates with clathrin in the presence of PP1, indicating clathrin pit entry is Src-independent; Lyn-deficient cells show diminished c-Kit internalization.\",\n      \"method\": \"Pharmacological inhibition (PP1); Lyn-knockout cell line; clathrin co-immunoprecipitation; receptor internalization assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inhibitor plus genetic KO approach with mechanistic dissection of internalization steps\",\n      \"pmids\": [\"10477727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"c-Kit signaling triggers two phosphorylation events on Microphthalmia (Mi): MAPK/ERK phosphorylates Ser73 (recruiting p300 coactivator and activating transactivation), and p90 Rsk-1 phosphorylates Ser409; together these couple Mi transactivation to ubiquitin-dependent proteasomal degradation. A double-unphosphorylatable mutant is stable but transcriptionally inert.\",\n      \"method\": \"Mutagenesis of Mi phosphorylation sites; ubiquitin-dependent degradation assay; kinase identification; transcriptional reporter assay\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis + kinase identification + degradation assay, multiple orthogonal methods\",\n      \"pmids\": [\"10673502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Constitutive activation of STAT3 (but not STAT1) by D816H mutant c-Kit is required for anchorage-independent growth and tumor formation; dominant-negative STAT3 inhibits mutant c-Kit-mediated tumorigenicity; constitutively active STAT3 restores transforming ability.\",\n      \"method\": \"Dominant-negative STAT3 transfection; constitutively active STAT3 rescue; colony formation and xenograft tumor assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with dominant-negative and rescue experiments, defined mechanistic pathway\",\n      \"pmids\": [\"11494148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The transmembrane ligand SCF contains a monomeric leucine-dependent basolateral targeting signal in its cytoplasmic domain, assisted by a cluster of acidic amino acids, enabling persistent cell-surface presentation to c-Kit; a leucine-to-alanine mutation in the Mgf-Sl17H mutant induces constitutive endocytosis instead.\",\n      \"method\": \"Site-directed mutagenesis of SCF cytoplasmic domain; epithelial cell surface expression assay; endocytosis assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-directed mutagenesis with functional cell biology readout\",\n      \"pmids\": [\"11152680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The SCL complex (containing SCL/TAL1, LMO2, GATA-1/2, E2A, Ldb-1) directly occupies and activates the c-kit promoter in hematopoietic progenitors via interaction with Sp1 at a GC-box motif; chromatin immunoprecipitation confirmed co-occupancy of SCL, E2A, and Sp1 at the c-kit promoter in vivo.\",\n      \"method\": \"Co-immunoprecipitation; chromatin immunoprecipitation (ChIP); transgenic mouse; transient transfection reporter assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in vivo, Co-IP of endogenous proteins, transgenic mouse, multiple orthogonal methods\",\n      \"pmids\": [\"12239153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of a c-Kit product complex reveals the kinase in a fully active conformation with ordered activation and phosphate-binding loops, providing the molecular basis for c-Kit kinase transactivation.\",\n      \"method\": \"X-ray crystallography of c-Kit kinase domain\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of active kinase complex\",\n      \"pmids\": [\"12824176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SCF activation of c-Kit in mast cells selectively induces release of IL-6 at concentrations that produce little or no release of TNF-alpha, leukotriene C4, histamine, or serotonin, demonstrating differential mediator release via c-Kit.\",\n      \"method\": \"SCF stimulation of bone marrow-derived mast cells; cytokine and mediator measurement assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with defined mediator readouts, single study\",\n      \"pmids\": [\"9108382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HIV-1 Nef protein transactivates the c-kit promoter, leading to c-Kit overexpression in astrocytes; overexpression of c-Kit in the absence of ligand induces apoptosis via the c-Kit tyrosine kinase domain.\",\n      \"method\": \"c-Kit overexpression in astrocyte cell line; kinase-dead mutant; c-kit promoter transactivation assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of kinase domain to define apoptotic mechanism, single study\",\n      \"pmids\": [\"9108086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GATA2 and Sp1 cooperatively activate the c-kit promoter in mast cells via a GC-box; GATA2 forms a complex with Sp1 on the promoter as shown by re-ChIP; Sp1 siRNA reduces both Sp1 and GATA2 occupancy, suppressing c-kit transcription; GATA2 knockdown reduces c-Kit cell-surface expression.\",\n      \"method\": \"Reporter assay; EMSA; chromatin immunoprecipitation (ChIP); re-ChIP; RNAi knockdown\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including re-ChIP and RNAi in a single study\",\n      \"pmids\": [\"20833840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"An engineered SCF partial agonist that impairs c-Kit dimerization truncates downstream signaling amplitude, producing biased activation of hematopoietic progenitors over mast cells; this demonstrates that c-Kit signaling output depends on receptor dimerization efficiency and that cell-type-specific responses can be tuned by partial agonism.\",\n      \"method\": \"Engineered SCF variant; c-Kit dimerization assay; in vitro and in vivo cell activation assays; mouse models of anaphylaxis and hematopoietic expansion\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanism-based engineering with multiple in vitro and in vivo validation experiments\",\n      \"pmids\": [\"28283060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Gαi1 and Gαi3 proteins associate with SCF-activated c-Kit, promoting c-Kit endocytosis and adaptor protein binding, thereby transducing downstream Akt-mTOR and Erk signaling; Gαi1/3 silencing or knockout attenuates SCF-induced HUVEC proliferation, migration, and tube formation in vitro, and retinal angiogenesis in vivo.\",\n      \"method\": \"Co-immunoprecipitation; siRNA/KO; dominant-negative and overexpression constructs; in vivo shRNA AAV injection; retinal angiogenesis assay\",\n      \"journal\": \"International Journal of Biological Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, multiple genetic tools (KO, DN, OE), in vitro and in vivo corroboration\",\n      \"pmids\": [\"37063428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"c-Kit is re-expressed in differentiating spermatogonia in the adult testis (not in stem cells); SCF from Sertoli cells stimulates DNA synthesis in type A spermatogonia in vitro; anti-c-Kit antibody injection blocks spermatogonial proliferation in vivo; a c-Kit point mutation abolishing PI3-kinase activation causes complete male sterility due to block of A1–A4 spermatogonial DNA synthesis. A truncated c-Kit product (tr-kit) expressed in post-meiotic spermatozoa triggers parthenogenetic egg activation upon microinjection.\",\n      \"method\": \"In vitro culture; antibody injection; point mutation analysis; microinjection of tr-kit into oocytes\",\n      \"journal\": \"Journal of Endocrinological Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple approaches: in vitro assay, in vivo antibody, mutation analysis with defined phenotype\",\n      \"pmids\": [\"11079457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Complex regulation of human c-kit transcription involves repressor elements (−4100 to −5500 region active in c-Kit-negative cells), and two Myb binding motifs: MYB1 (bound by c-Myb, acts as partial repressor) and MYB2 (essential positive element not bound by c-Myb).\",\n      \"method\": \"Promoter deletion/reporter assays; EMSA; site-directed mutation of Myb motifs\",\n      \"journal\": \"Cell Growth & Differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assays with mutagenesis and EMSA, single study\",\n      \"pmids\": [\"8891342\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KIT (CD117) is a type III receptor tyrosine kinase that, upon binding its ligand SCF, undergoes homodimerization (regulated by Gαi1/3 and the GNNK isoform splice variant) and trans-autophosphorylation, activating downstream PI3K/Akt-mTOR, Ras-Raf-MAPK, JAK/STAT, and Src family kinase cascades; MAPK phosphorylates the transcription factor MITF at Ser73 (recruiting p300/CBP) while p90 Rsk-1 phosphorylates MITF at Ser409, coupling transactivation to proteasomal degradation, and constitutive juxtamembrane or activation-loop mutations (e.g., D816V) bypass ligand dependence to constitutively activate STAT3 and drive oncogenesis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"c-KIT encodes a 145 kDa transmembrane glycoprotein receptor tyrosine kinase structurally related to CSF-1 receptor and PDGF receptor, capable of self-phosphorylation on tyrosine residues; it was identified as a cell surface receptor for an unidentified ligand.\",\n      \"method\": \"cDNA cloning, peptide antibody identification, autophosphorylation assay in glioblastoma cells and transfected fibroblasts\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original structural characterization with in vitro kinase assay, foundational paper\",\n      \"pmids\": [\"2448137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"c-KIT (encoded at the W locus) functions as a transmembrane receptor tyrosine kinase essential for development of hematopoietic, melanocyte, and germ cell lineages; W mutations impair kinase activity in mast cells from W/Wv mice.\",\n      \"method\": \"Genetic linkage of c-kit to W locus, kinase activity assay in W mutant mast cells, expression studies\",\n      \"journal\": \"Ciba Foundation symposium\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis plus functional kinase assay, replicated across multiple labs\",\n      \"pmids\": [\"1690623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"MGF (mast cell growth factor) is a ligand for c-KIT; 125I-labeled MGF cross-links to c-kit-expressing cells and the complex is immunoprecipitated with anti-c-kit antiserum, establishing MGF as the c-KIT ligand.\",\n      \"method\": \"Ligand purification, [3H]thymidine proliferation assay, 125I cross-linking, immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct receptor-ligand cross-linking and immunoprecipitation, highly cited foundational paper\",\n      \"pmids\": [\"1698553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"c-KIT protein is expressed on the surface of oocytes (primordial through full-grown) and spermatogonia, and has autophosphorylation activity in the ovary; its expression correlates with oocyte growth and gonial proliferation in germ cells.\",\n      \"method\": \"RNA blot analysis, in situ hybridization, indirect immunofluorescence, immune complex kinase assay\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct protein detection with autophosphorylation assay, replicated in multiple germ cell studies\",\n      \"pmids\": [\"1712701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"c-KIT signaling is required for the development of intestinal pacemaker cells (interstitial cells of Cajal); blockade with antagonistic anti-c-kit monoclonal antibody in neonatal mice and W/Wv mice results in defective autonomous gut pacing and lethal paralytic ileus.\",\n      \"method\": \"Anti-c-kit monoclonal antibody blockade in vivo, physiological analysis of gut motility in W/Wv mice\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and antibody loss-of-function with defined physiological readout, highly cited\",\n      \"pmids\": [\"1283735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"c-KIT cooperates with erythropoietin in erythroid progenitor proliferation; anti-c-Kit antibody inhibits proliferation but not differentiation during the early phase of erythropoietin response, and erythropoietin downregulates c-kit gene expression.\",\n      \"method\": \"Anti-c-Kit antibody inhibition in culture, erythroid progenitor colony assay, gene expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional antibody blockade with defined proliferation readout, single lab\",\n      \"pmids\": [\"1374312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Two point mutations in c-KIT coding sequence (Val560Gly and Asp816Val) in mast cell leukemia line HMC-1 cause ligand-independent constitutive autophosphorylation and activation of c-KIT; Asp816Val alone is sufficient for constitutive activation as demonstrated by site-directed mutagenesis in 293T cells.\",\n      \"method\": \"cDNA sequencing, site-directed mutagenesis, immune complex kinase assay, tyrosine phosphorylation detection in transfected cells\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis in heterologous cells, foundational mechanistic paper\",\n      \"pmids\": [\"7691885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SCF binding to c-KIT induces receptor dimerization, kinase activation, and tyrosine phosphorylation of SH2-containing signaling molecules; downstream, Syp phosphatase associates with activated c-KIT via both its SH2 domains, becomes phosphorylated on tyrosine, and forms a complex with Grb2, linking c-KIT to Ras-Raf-MAP kinase activation.\",\n      \"method\": \"GST-SH2 domain pulldown, co-immunoprecipitation, in vitro binding assay, Ras activation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal pulldowns and Co-IP with in vitro binding confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"7523381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SCF/c-KIT interaction regulates oocyte growth in vitro; immune complex kinase assay demonstrates ovarian c-KIT autophosphorylation activity; anti-c-kit antibody (ACK2) severely inhibits oocyte growth in coculture.\",\n      \"method\": \"Immune complex kinase assay, oocyte culture with exogenous KL, ACK2 antibody blockade, Northern analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct kinase assay plus antibody loss-of-function, multiple orthogonal methods\",\n      \"pmids\": [\"7507447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A missense mutation in the KIT tyrosine kinase domain (Gly664Arg) causes piebaldism in humans, establishing that loss-of-function KIT mutations lead to melanocyte absence.\",\n      \"method\": \"Genetic linkage analysis, DNA sequencing of KIT gene in piebaldism family\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — segregation with phenotype in family plus sequencing, replicated across species\",\n      \"pmids\": [\"1717985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A somatic Asp816Val point mutation in the catalytic domain of c-KIT causes ligand-independent autophosphorylation and is found in peripheral blood mononuclear cells of mastocytosis patients with associated hematologic disorders.\",\n      \"method\": \"RT-PCR, DNA sequencing of patient samples, correlation with ligand-independent autophosphorylation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutation identified in patient tissue, correlated with known constitutive activation mechanism\",\n      \"pmids\": [\"7479840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Somatic activating c-KIT mutation (Asp816Val codon substitution) causes constitutive KIT receptor activation in mast cells of skin and spleen in urticaria pigmentosa/aggressive mastocytosis, establishing clonal and neoplastic nature of this disease.\",\n      \"method\": \"Tissue microdissection, DNA sequencing, demonstration of constitutive KIT activation\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in situ mutation identified in purified neoplastic mast cells, first in situ demonstration\",\n      \"pmids\": [\"8589724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SCF stimulation of mast cells via c-KIT induces differential release of IL-6, producing >100-fold more IL-6 than unstimulated cells, at concentrations causing little histamine, TNF-alpha, or leukotriene C4 release, demonstrating a selective signaling output of c-KIT.\",\n      \"method\": \"ELISA measurement of cytokine/mediator release from bone marrow-derived mast cells after SCF stimulation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cellular functional readout with dose-response, single lab\",\n      \"pmids\": [\"9108382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HIV-1 Nef protein transactivates the c-kit promoter; overexpression of c-KIT in astrocytes induces apoptosis requiring the c-KIT tyrosine kinase domain, demonstrating a pro-apoptotic role for c-KIT in astrocytes.\",\n      \"method\": \"Promoter reporter assay, c-kit overexpression in astrocyte cell line, kinase domain mutagenesis, apoptosis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter transactivation plus kinase domain requirement for apoptosis, single lab with multiple methods\",\n      \"pmids\": [\"9108086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SCF stimulation of melanoma cells activates MAP kinase, which phosphorylates the transcription factor Microphthalmia (Mi) at a consensus serine, upregulating Mi-dependent transactivation of the tyrosinase gene promoter; this defines a KIT→MAPK→Mi signaling axis in melanocytes.\",\n      \"method\": \"SCF stimulation assay, MAP kinase activation, site-directed mutagenesis of Mi phosphorylation site, luciferase reporter assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical pathway delineation with mutagenesis and reporter assay, highly cited\",\n      \"pmids\": [\"9440696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"c-KIT signaling via MAPK phosphorylation of Mi recruits the transcriptional coactivator p300/CBP specifically to phospho-Mi, enhancing Mi transcriptional activity; phosphorylation does not alter Mi nuclear localization, DNA binding, or dimerization.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, phosphorylation-specific interaction assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with defined mechanistic consequence, replicated by Fisher lab\",\n      \"pmids\": [\"9660747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SCF induces dose-dependent c-KIT receptor dimerization detectable by FRET within 3 minutes, followed by receptor capping and internalization; c-KIT is not recycled to the cell surface after internalization. Erythropoietin, but not thrombopoietin, also induces c-KIT dimerization and tyrosine phosphorylation, indicating Epo-c-Kit cross-talk.\",\n      \"method\": \"FRET with fluorochrome-conjugated anti-c-Kit antibodies, flow cytometry, confocal microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — FRET-based dimerization assay with kinetic analysis and confocal microscopy\",\n      \"pmids\": [\"9446650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Gastrointestinal stromal tumors harbor gain-of-function mutations in c-KIT in the juxtamembrane region; mutant KIT proteins are constitutively activated without SCF; transfection of mutant c-kit cDNA causes malignant transformation of Ba/F3 cells; GISTs may originate from interstitial cells of Cajal.\",\n      \"method\": \"cDNA sequencing, stable transfection/transformation assay in Ba/F3 cells, immunohistochemistry\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — gain-of-function mutagenesis with transformation assay, most highly cited paper in field\",\n      \"pmids\": [\"9438854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Familial GISTs harbor germline mutations in the KIT gene, establishing that KIT germline mutations predispose to GIST development.\",\n      \"method\": \"Germline DNA sequencing in familial GIST kindred\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — germline mutation identified with co-segregation with disease phenotype\",\n      \"pmids\": [\"9697690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"c-KIT juxtamembrane mutations in canine mastocytomas cause constitutive (ligand-independent) tyrosine phosphorylation of KIT, providing in situ evidence that the juxtamembrane region normally inhibits receptor kinase activity.\",\n      \"method\": \"cDNA sequencing from tumor tissue, tyrosine phosphorylation assay in mast cell lines\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in situ mutation with functional phosphorylation readout, multiple mutation types confirmed\",\n      \"pmids\": [\"9989791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The Asp816Val activating mutation in c-KIT causes germ cell tumors; this mutation results in constitutively activated, tyrosine-phosphorylated KIT kinase in transfected cells.\",\n      \"method\": \"DNA sequencing of tumor tissue, cell transfection, tyrosine phosphorylation assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — transfection with constitutive activation demonstrated by phosphorylation assay\",\n      \"pmids\": [\"10362788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"c-KIT phosphatidylinositol 3-kinase (PI3K) activation is specifically required for spermatogonial differentiation but not for primordial germ cell maintenance; a point mutation abolishing PI3K binding causes complete male sterility due to failure of DNA synthesis in differentiating spermatogonia.\",\n      \"method\": \"PI3K-binding point mutation knock-in mouse, spermatogonia proliferation assay, DNA synthesis measurement\",\n      \"journal\": \"Journal of endocrinological investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with specific signaling pathway mutation and defined cellular phenotype\",\n      \"pmids\": [\"11079457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A truncated c-kit product (tr-kit) expressed specifically in post-meiotic spermatids and mature sperm, when microinjected into mouse eggs, causes parthenogenetic activation, suggesting tr-kit plays a role in fertilization.\",\n      \"method\": \"Microinjection of tr-kit into mouse eggs, parthenogenetic activation assay\",\n      \"journal\": \"Journal of endocrinological investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional microinjection assay, single lab\",\n      \"pmids\": [\"11079457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Src family kinase signaling is required for SCF-induced c-KIT internalization; PP1 (Src family kinase inhibitor) blocks capping and internalization of c-KIT; c-KIT can associate with clathrin independently of Src kinases; disruption of Lyn kinase expression also diminishes SCF-induced c-KIT internalization.\",\n      \"method\": \"PP1 inhibitor treatment, Lyn-deficient cell line, c-KIT trafficking assay, clathrin co-precipitation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic inhibition with defined trafficking readout, multiple orthogonal approaches\",\n      \"pmids\": [\"10477727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GNNK- isoform of c-KIT (lacking 4 amino acids in juxtamembrane extracellular region) shows more rapid and extensive tyrosine autophosphorylation, faster internalization, and stronger MAP kinase phosphorylation than GNNK+ isoform after ligand stimulation, resulting in superior transforming activity in NIH3T3 cells.\",\n      \"method\": \"Isoform expression in NIH3T3 cells, autophosphorylation assay, MAP kinase phosphorylation, colony formation, focus formation, nude mouse tumorigenicity\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — comparative isoform analysis with multiple functional assays and kinase measurements\",\n      \"pmids\": [\"10523834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Activating mutations of c-KIT at Asp816 cause constitutive STAT3 and STAT1 activation; dominant negative STAT3 (but not STAT1) inhibits mutant c-Kit-mediated anchorage-independent growth and tumor formation, and constitutively active STAT3 restores transforming ability.\",\n      \"method\": \"Transfection of dominant negative STAT3/STAT1, anchorage-independent growth assay, in vivo tumor formation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with dominant negatives and rescue experiment, in vitro and in vivo readouts\",\n      \"pmids\": [\"11494148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"c-KIT signaling triggers two phosphorylation events on Microphthalmia (Mi): MAPK/ERK targets Ser73 (upregulating transactivation and recruiting p300 coactivator) and p90 Rsk-1 targets Ser409; together these phosphorylations couple Mi transactivation to ubiquitin-dependent proteasomal degradation, creating short-lived Mi activation.\",\n      \"method\": \"Site-directed mutagenesis of Mi phosphorylation sites, reporter assay, co-immunoprecipitation with p300, ubiquitin-dependent degradation assay, protein stability measurement\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with multiple orthogonal readouts (transcription, degradation, coactivator recruitment), single rigorous paper\",\n      \"pmids\": [\"10673502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The cytoplasmic domain of stem cell factor (SCF) contains a monomeric leucine-dependent basolateral targeting signal assisted by a cluster of acidic amino acids; this signal allows persistent cell surface exposure of SCF for c-KIT signaling; a mutated SCF (Mgf Sl17H) instead induces constitutive endocytosis via a lysosomal targeting motif.\",\n      \"method\": \"Site-directed mutagenesis of SCF cytoplasmic domain, polarized epithelial cell expression, cell surface biotinylation, endocytosis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with defined sorting assays, multiple orthogonal methods\",\n      \"pmids\": [\"11152680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The SCL/TAL1 transcription factor complex (containing SCL, LMO2, GATA-1/2, E2A, Ldb-1) directly activates the c-kit promoter in hematopoietic cells by tethering via Sp1 zinc finger interaction at a GC-box; chromatin immunoprecipitation demonstrates SCL, E2A, and Sp1 co-occupy the c-kit promoter in vivo.\",\n      \"method\": \"Transient transfection reporter assay, co-immunoprecipitation of endogenous proteins, transgenic mouse model, chromatin immunoprecipitation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo ChIP and transgenic model\",\n      \"pmids\": [\"12239153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pharmacological dimerization of membrane-targeted c-KIT-FKBP12 fusion proteins using FK1012 or AP1510 is sufficient to activate c-KIT signaling and rescue Ba/F3 cells from IL-3 dependence, demonstrating that receptor dimerization alone is sufficient for c-KIT proliferative signaling.\",\n      \"method\": \"Chemical dimerizer-induced receptor dimerization, cell proliferation assay, IL-3 independence rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution of minimal dimerization requirement, clean functional readout\",\n      \"pmids\": [\"9446649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"KIT and PDGFRA mutations are alternative and mutually exclusive oncogenic mechanisms in GISTs; ~35% of GISTs lacking KIT mutations have activating PDGFRA mutations; tumors with either KIT or PDGFRA oncoproteins activate the same downstream signaling intermediates.\",\n      \"method\": \"Mutation sequencing, Western blot for downstream signaling, cytogenetic analysis\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutational analysis with downstream signaling comparison, highly cited\",\n      \"pmids\": [\"12522257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The Asp816Val 'enzymatic site type' (EST) KIT mutation is resistant to imatinib (STI571) and SU9529 even at 10 µM, while juxtamembrane 'regulatory type' (RT) KIT mutations are sensitive; this classifies KIT mutations into two pharmacologically distinct categories.\",\n      \"method\": \"COS cell expression of wild-type and mutant KIT, kinase inhibition assay, HMC-1 subclone proliferation and apoptosis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — kinase assay with isogenic cell lines differing only in mutation type, mechanistic framework established\",\n      \"pmids\": [\"11861291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of c-KIT in a fully active phosphorylated product complex reveals ordered kinase activation and phosphate-binding loops, providing molecular basis for c-KIT kinase transactivation.\",\n      \"method\": \"X-ray crystallography of c-KIT phosphorylated product complex\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation context\",\n      \"pmids\": [\"12824176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The c-kit promoter region contains a DNA sequence that forms a stable intramolecular G-quadruplex structure under physiological conditions, as characterized by NMR, circular dichroism, and melting temperature measurements; this quadruplex may regulate c-kit transcription.\",\n      \"method\": \"NMR, circular dichroism, UV melting temperature analysis\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods confirming quadruplex formation\",\n      \"pmids\": [\"16045346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A second G-quadruplex-forming sequence (c-kit21) in the c-KIT promoter upstream of the transcription initiation site forms parallel quadruplexes under physiological conditions; mutational analysis reveals structural polymorphism; the sequence is highly conserved across human, mouse, rat, and chimpanzee.\",\n      \"method\": \"NMR, circular dichroism, UV spectroscopy, mutational analysis of quadruplex-forming sequence\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods with mutational dissection of the quadruplex\",\n      \"pmids\": [\"16784237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Primary and secondary KIT mutation location determines sunitinib sensitivity; secondary KIT exon 13/14 mutations (ATP-binding pocket) confer sensitivity to sunitinib while exon 17/18 mutations (activation loop) confer resistance; biochemical profiling of specific mutants confirmed clinical findings.\",\n      \"method\": \"Tumor sequencing, biochemical profiling of KIT mutants in vitro, clinical outcome correlation in phase I/II trial\",\n      \"journal\": \"Journal of clinical oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical profiling of specific mutants combined with clinical validation\",\n      \"pmids\": [\"18955458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GATA2 and Sp1 co-occupy the c-kit promoter GC-box in mast cells and cooperatively transactivate c-kit; GATA2 is recruited to the c-kit promoter in a mast cell-specific manner by forming a complex with Sp1; siRNA knockdown of either factor reduces c-kit transcription and cell surface c-KIT expression.\",\n      \"method\": \"Reporter assay, EMSA, chromatin immunoprecipitation, re-ChIP, siRNA knockdown, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo ChIP and functional knockdown\",\n      \"pmids\": [\"20833840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Engineered SCF partial agonist that impairs c-KIT dimerization truncates downstream signaling amplitude, resulting in biased activation of hematopoietic progenitors over mast cells; this demonstrates that signal amplitude (tuned by c-KIT dimerization efficiency) determines cell-type-specific biological outputs.\",\n      \"method\": \"SCF engineering, receptor dimerization assay, in vitro and in vivo cell activation assays, mouse models of anaphylaxis and hematopoietic expansion\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanism-based receptor engineering with multiple in vitro and in vivo readouts\",\n      \"pmids\": [\"28283060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Gαi1 and Gαi3 proteins associate with SCF-activated c-KIT, promote c-KIT endocytosis and adaptor protein binding, and are required for downstream Akt-mTOR and Erk activation; endothelial knockdown of Gαi1/3 suppresses SCF-induced retinal angiogenesis in vivo.\",\n      \"method\": \"Co-immunoprecipitation, Gαi1/3 siRNA/KO, dominant negative mutants, overexpression, HUVEC proliferation/migration/tube formation assay, in vivo AAV-mediated endothelial knockdown in retinal angiogenesis model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus multiple genetic perturbations with in vivo validation\",\n      \"pmids\": [\"37063428\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KIT is a type III receptor tyrosine kinase that, upon binding its ligand SCF/MGF, undergoes homodimerization (requiring sufficient dimerization for full signal amplitude), autophosphorylation, and activation of multiple downstream cascades including PI3K, MAPK/ERK, JAK/STAT3, and Src family kinases, with Gαi1/3 proteins facilitating c-KIT endocytosis and signal transduction; MAPK-mediated phosphorylation of the transcription factor Microphthalmia couples KIT signaling to melanocyte gene expression and proteasomal degradation; juxtamembrane mutations constitutively activate KIT (sensitive to imatinib), while activation-loop mutations (e.g., Asp816Val) confer imatinib resistance; the c-kit promoter contains conserved G-quadruplex structures and is transcriptionally regulated by SCL/TAL1 complex and GATA2/Sp1 in a cell-type-specific manner.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"KIT (CD117) is a type III receptor tyrosine kinase that functions as the receptor for stem cell factor (SCF) and is essential for development and homeostasis of melanocytes, erythroid progenitors, germ cells, mast cells, and interstitial cells of Cajal [PMID:1698553, PMID:1690623, PMID:1283735]. SCF binding induces rapid KIT homodimerization and trans-autophosphorylation, recruiting SH2-domain adaptors including SHP-2/Grb2 to activate PI3K/Akt-mTOR, Ras-Raf-MAPK, JAK/STAT, and Src family kinase cascades; dimerization efficiency tunes signaling amplitude and cell-type-selective output, and Gαi1/3 proteins promote KIT endocytosis and downstream Akt-mTOR/Erk transduction [PMID:7523381, PMID:10582339, PMID:28283060, PMID:37063428]. In melanocytes, the MAPK cascade phosphorylates the transcription factor MITF at Ser73 to recruit p300/CBP, while p90 Rsk-1 phosphorylates Ser409, coupling MITF transactivation to ubiquitin-dependent proteasomal degradation [PMID:9440696, PMID:10673502]. Gain-of-function mutations in the juxtamembrane or activation-loop domains cause ligand-independent kinase activity and constitutive STAT3 activation sufficient for transformation [PMID:9989791, PMID:11494148].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing the receptor–ligand pair: biochemical cross-linking demonstrated that SCF (MGF/KL) is the direct ligand for c-Kit, resolving the identity of the signal that activates this orphan receptor tyrosine kinase.\",\n      \"evidence\": \"125I-labeled MGF cross-linking to c-Kit-expressing cells followed by anti-c-Kit immunoprecipitation\",\n      \"pmids\": [\"1698553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the SCF–KIT complex not yet defined\", \"No structural information on the ligand–receptor interface\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Defining developmental requirement: genetic analysis of W/Wv mice showed that c-Kit kinase activity is cell-autonomously required in erythrocytes, melanocytes, germ cells, and mast cells, establishing KIT as a master regulator of multiple lineages.\",\n      \"evidence\": \"Kinase activity assay in W/Wv mutant mast cells; multi-lineage phenotyping in W mutant mice\",\n      \"pmids\": [\"1690623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lineage-specific downstream effectors not identified\", \"Contribution of SCF availability versus intrinsic KIT signaling not separated\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Extending KIT's physiological scope beyond hematopoiesis: anti-c-Kit antibody blockade abolished gut pacemaker activity, establishing KIT as essential for interstitial cells of Cajal and intestinal motility.\",\n      \"evidence\": \"In vivo anti-c-Kit antibody treatment; gut motility physiology in neonatal mice\",\n      \"pmids\": [\"1283735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathways in ICC not delineated\", \"Whether KIT is needed for ICC survival or function not distinguished\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapping the proximal signaling mechanism: SCF binding induces KIT dimerization and trans-autophosphorylation, and SHP-2 associates with activated KIT via SH2 domains and then complexes with Grb2, linking KIT to Ras/Raf activation.\",\n      \"evidence\": \"Reciprocal Co-IP, GST pulldown, and in vitro binding assays in SCF-stimulated cells\",\n      \"pmids\": [\"7523381\", \"7531500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphotyrosine docking sites on KIT for SHP-2 not mapped\", \"PI3K and STAT pathway connections not yet defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Linking KIT to transcription factor regulation: MAPK downstream of SCF/KIT phosphorylates MITF at a consensus serine, enabling p300/CBP recruitment and transactivation of pigmentation genes, explaining how KIT controls melanocyte differentiation.\",\n      \"evidence\": \"MAPK phosphorylation assay; MITF mutant analysis; Co-IP showing phospho-MITF–p300 interaction; reporter assays in melanoma cells\",\n      \"pmids\": [\"9440696\", \"9660747\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other KIT-regulated transcription factors in melanocytes unknown\", \"Whether p300 recruitment is sufficient for target gene selectivity unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating dimerization sufficiency: FRET-based detection showed SCF induces KIT dimerization within minutes, and chemical dimerization of the KIT cytoplasmic domain alone sufficed to trigger proliferative signaling, establishing dimerization as the minimal activation event.\",\n      \"evidence\": \"FRET on intact cells; chemical dimerization of FKBP12-KIT fusion; cell proliferation assay\",\n      \"pmids\": [\"9446650\", \"9446649\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimerization geometry affects signaling quality not addressed\", \"Role of extracellular domain contacts beyond ligand bridging unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identifying isoform-specific and Src-dependent regulation: the GNNK− splice isoform shows enhanced autophosphorylation and transforming activity versus GNNK+, and Src family kinases are required for KIT internalization, dissecting regulatory layers in receptor trafficking.\",\n      \"evidence\": \"Isoform comparison in NIH3T3 transformation and signaling assays; PP1 inhibitor plus Lyn-KO cells for internalization\",\n      \"pmids\": [\"10523834\", \"10477727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for GNNK isoform differences not resolved\", \"Identity of the specific Src family member primarily responsible in vivo unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Characterizing gain-of-function mutations: juxtamembrane mutations produce constitutive ligand-independent KIT phosphorylation, and downstream signaling through multiple cascades (PI3K, Src, JAK/STAT, MAPK) was comprehensively mapped.\",\n      \"evidence\": \"Sequencing of tumor-derived KIT mutations; phosphorylation assays; pathway inhibitor analysis in hematopoietic cells\",\n      \"pmids\": [\"9989791\", \"10582339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Activation-loop mutations (D816V class) not yet mechanistically distinguished from juxtamembrane mutations\", \"No structural explanation for autoinhibition relief\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Coupling transactivation to degradation: dual phosphorylation of MITF by MAPK (Ser73) and p90Rsk-1 (Ser409) downstream of KIT links transcriptional activation to ubiquitin-dependent proteasomal degradation, revealing a self-limiting signaling circuit.\",\n      \"evidence\": \"Mutagenesis of Ser73 and Ser409; ubiquitin-dependent degradation assay; kinase identification; reporter assay\",\n      \"pmids\": [\"10673502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase responsible for MITF degradation not identified\", \"Whether this coupling operates identically in melanocyte stem cells unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying the oncogenic effector of activating mutants: constitutive STAT3 activation by the D816H KIT mutant is necessary and sufficient for transformation, as dominant-negative STAT3 blocks and constitutively active STAT3 rescues tumorigenic growth.\",\n      \"evidence\": \"Dominant-negative and constitutively active STAT3 epistasis in colony formation and xenograft assays\",\n      \"pmids\": [\"11494148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"STAT3 target genes mediating transformation not defined\", \"Whether other oncogenic KIT mutations also depend on STAT3 not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Providing structural basis for kinase activation: the crystal structure of the KIT kinase domain in a product complex showed the fully active conformation with ordered activation and phosphate-binding loops.\",\n      \"evidence\": \"X-ray crystallography of KIT kinase domain\",\n      \"pmids\": [\"12824176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Autoinhibited (inactive) conformation not structurally resolved in this study\", \"Full-length ectodomain–ligand complex structure lacking\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating tunable signaling through partial agonism: an engineered SCF variant that impairs KIT dimerization efficiency biases signaling to favor hematopoietic progenitor expansion over mast cell activation, showing that receptor dimer geometry controls cell-type selectivity.\",\n      \"evidence\": \"Engineered SCF partial agonist; dimerization assay; in vitro and in vivo hematopoietic and mast cell readouts; mouse anaphylaxis model\",\n      \"pmids\": [\"28283060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for partial agonism at the dimer interface not resolved\", \"Long-term hematopoietic reconstitution effects not assessed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealing heterotrimeric G protein involvement: Gαi1/3 associate with activated KIT and promote its endocytosis and adaptor recruitment, transducing Akt-mTOR and Erk signaling critical for endothelial cell proliferation and angiogenesis.\",\n      \"evidence\": \"Reciprocal Co-IP; siRNA/KO; dominant-negative and overexpression constructs; in vivo AAV-shRNA; retinal angiogenesis model\",\n      \"pmids\": [\"37063428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface between Gαi and KIT cytoplasmic domain not mapped\", \"Whether Gαi modulates KIT signaling in classical KIT-dependent lineages (mast cells, melanocytes) untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the full-length ectodomain structure of the SCF–KIT dimer complex, the E3 ligase mediating MITF degradation downstream of KIT, and whether Gαi-dependent endocytic signaling operates across all KIT-dependent cell types.\",\n      \"evidence\": \"Not applicable — open question\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length SCF–KIT dimer structure available\", \"MITF E3 ligase identity unknown\", \"Gαi role not tested in melanocytes, germ cells, or ICC\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 6, 11, 13, 19]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [5, 19]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 17]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 5, 9, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5, 9, 12, 17, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [6, 7, 13, 15, 16, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 7, 13, 15, 16, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 4, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [18, 22, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KITLG\",\n      \"SHP2\",\n      \"GRB2\",\n      \"MITF\",\n      \"STAT3\",\n      \"GNAI1\",\n      \"GNAI3\",\n      \"LYN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"KIT is a type III receptor tyrosine kinase that, upon binding its ligand stem cell factor (SCF/MGF), undergoes rapid homodimerization, autophosphorylation, and activation of PI3K, MAPK/ERK, JAK/STAT3, and Src family kinase cascades to govern the development, proliferation, and survival of hematopoietic progenitors, melanocytes, germ cells, interstitial cells of Cajal, and mast cells [PMID:1698553, PMID:1690623, PMID:1283735, PMID:7507447]. SCF-induced KIT dimerization efficiency controls signaling amplitude and cell-type-selective biological output, with engineered partial agonists demonstrating that reduced dimerization biases activation toward hematopoietic progenitors over mast cells [PMID:28283060, PMID:9446650]. Downstream, MAPK phosphorylates the transcription factor Microphthalmia (MITF) to recruit p300/CBP and couple transactivation of melanocyte genes to ubiquitin-dependent proteasomal degradation of MITF, while Gαi1/3 proteins facilitate KIT endocytosis and Akt-mTOR/Erk signaling [PMID:9440696, PMID:10673502, PMID:37063428]. Gain-of-function KIT mutations in the juxtamembrane domain cause gastrointestinal stromal tumors (GISTs) and are imatinib-sensitive, whereas activation-loop mutations (notably Asp816Val) constitutively activate STAT3-dependent transformation and confer imatinib resistance, and germline loss-of-function mutations cause piebaldism [PMID:9438854, PMID:11861291, PMID:1717985].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Identifying KIT as a transmembrane receptor tyrosine kinase with intrinsic autophosphorylation activity established the molecular framework for understanding how a proto-oncogene product could transduce extracellular signals.\",\n      \"evidence\": \"cDNA cloning and autophosphorylation assay in glioblastoma cells and transfected fibroblasts\",\n      \"pmids\": [\"2448137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity unknown at this point\", \"Downstream signaling targets uncharacterized\", \"No structural information on the kinase domain\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Genetic mapping of c-kit to the W locus and identification of SCF/MGF as its ligand resolved a decades-old question about what receptor-ligand system governs hematopoietic, melanocyte, and germ cell development.\",\n      \"evidence\": \"Genetic linkage of c-kit to W locus with kinase activity assays in W mutant mast cells; 125I-MGF cross-linking and immunoprecipitation confirming ligand identity\",\n      \"pmids\": [\"1690623\", \"1698553\", \"1712701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of receptor activation upon ligand binding unknown\", \"Downstream signaling cascades uncharacterized\", \"Tissue-specific roles beyond hematopoiesis/melanocytes/germ cells not yet explored\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrating that KIT signaling is required for interstitial cells of Cajal development and gut pacemaking revealed a non-hematopoietic physiological role and broadened the range of KIT-dependent cell lineages.\",\n      \"evidence\": \"Anti-c-kit antibody blockade in neonatal mice and W/Wv mutant gut motility analysis\",\n      \"pmids\": [\"1283735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which KIT supports ICC differentiation unknown\", \"Whether KIT signals differently in ICC vs. mast cells not addressed\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Discovery of constitutively activating KIT point mutations (Val560Gly and Asp816Val) in mast cell leukemia established that somatic gain-of-function mutations in KIT drive neoplasia, creating the conceptual basis for targeted therapy.\",\n      \"evidence\": \"cDNA sequencing of HMC-1 cells, site-directed mutagenesis with reconstitution in 293T cells showing ligand-independent autophosphorylation\",\n      \"pmids\": [\"7691885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How juxtamembrane vs. activation-loop mutations differ mechanistically was unclear\", \"Therapeutic targetability not yet tested\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Delineation of the KIT→Syp/Grb2→Ras-Raf-MAPK signaling axis resolved how ligand-induced KIT dimerization couples to mitogenic signaling.\",\n      \"evidence\": \"GST-SH2 pulldown, co-immunoprecipitation, and Ras activation assay after SCF stimulation\",\n      \"pmids\": [\"7523381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PI3K and STAT pathways downstream of KIT not yet characterized\", \"Signaling specificity between KIT isoforms unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of KIT loss-of-function mutations in piebaldism families and Asp816Val in mastocytosis patients established a clinical mutation spectrum spanning both loss- and gain-of-function phenotypes.\",\n      \"evidence\": \"Genetic linkage and DNA sequencing in piebaldism kindred; RT-PCR sequencing of patient blood in mastocytosis\",\n      \"pmids\": [\"1717985\", \"7479840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype correlation for different KIT domains incomplete\", \"Mechanism by which loss-of-function selectively affects melanocytes unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Simultaneous discoveries that KIT→MAPK phosphorylates MITF to recruit p300/CBP for melanocyte gene transactivation, and that juxtamembrane KIT mutations drive GISTs, connected KIT signaling to both normal transcriptional programming and solid tumor oncogenesis.\",\n      \"evidence\": \"SCF stimulation with MAPK-dependent MITF phosphorylation and reporter assay; cDNA sequencing of GISTs with Ba/F3 transformation assay; germline KIT mutation in familial GIST\",\n      \"pmids\": [\"9440696\", \"9660747\", \"9438854\", \"9697690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MITF phosphorylation is coupled to its proteasomal degradation unknown\", \"Structural basis for juxtamembrane autoinhibition not resolved\", \"Whether GIST signaling differs from normal ICC signaling unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Functional dissection of KIT downstream pathways revealed that PI3K binding is specifically required for spermatogonial differentiation, Src kinases control KIT internalization, GNNK- isoform has enhanced signaling, and Asp816Val activates STAT3 for transformation — establishing pathway-selective and isoform-specific outputs.\",\n      \"evidence\": \"PI3K-binding knock-in mouse with male sterility; PP1 inhibition and Lyn-deficient cells blocking KIT internalization; GNNK± isoform comparison in NIH3T3; dominant-negative STAT3 blocking Asp816Val transformation\",\n      \"pmids\": [\"11079457\", \"10477727\", \"10523834\", \"11494148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of PI3K, STAT3, MAPK signals into a unified model lacking\", \"How isoform expression is regulated in different tissues unknown\", \"Whether STAT3 is required for all gain-of-function mutants unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that MAPK and Rsk-1 dual phosphorylation of MITF couples transcriptional activation to ubiquitin-dependent degradation resolved how KIT produces short-lived bursts of melanocyte gene expression.\",\n      \"evidence\": \"Site-directed mutagenesis of MITF Ser73 and Ser409, reporter assay, p300 co-IP, and proteasomal degradation assay\",\n      \"pmids\": [\"10673502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for phospho-MITF ubiquitination unidentified\", \"Whether this coupling mechanism operates in non-melanocyte KIT-expressing cells unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Pharmacological classification of KIT mutations into imatinib-sensitive juxtamembrane and imatinib-resistant activation-loop categories, together with forced-dimerization experiments proving dimerization sufficiency, provided the mechanistic logic for mutation-specific targeted therapy.\",\n      \"evidence\": \"COS cell kinase inhibition assays comparing juxtamembrane vs. Asp816Val mutants with imatinib/SU9529; FKBP12-based chemical dimerization rescue of Ba/F3 cells\",\n      \"pmids\": [\"11861291\", \"9446649\", \"12522257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for imatinib resistance at Asp816 not solved\", \"Secondary resistance mechanisms not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The crystal structure of the phosphorylated KIT kinase domain in a product complex provided the first atomic-resolution view of the active conformation, explaining transactivation geometry and informing inhibitor design.\",\n      \"evidence\": \"X-ray crystallography of phosphorylated c-KIT kinase domain\",\n      \"pmids\": [\"12824176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length KIT or KIT–SCF complex unavailable\", \"How Asp816Val alters the activation loop conformation structurally unresolved at this time\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery of conserved G-quadruplex structures in the KIT promoter introduced a novel layer of transcriptional regulation potentially targetable by small molecules.\",\n      \"evidence\": \"NMR, circular dichroism, and UV melting analysis of two G-quadruplex-forming sequences in the c-kit promoter\",\n      \"pmids\": [\"16045346\", \"16784237\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of quadruplex formation on KIT transcription not demonstrated in cells\", \"No quadruplex-binding compounds tested for transcriptional effect\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying GATA2/Sp1 cooperative transactivation of the c-kit promoter in mast cells, complementing the earlier SCL/TAL1 complex in hematopoietic progenitors, revealed cell-type-specific transcriptional control of KIT expression.\",\n      \"evidence\": \"ChIP, re-ChIP, EMSA, and siRNA knockdown in mast cells showing GATA2–Sp1 co-occupancy\",\n      \"pmids\": [\"20833840\", \"12239153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How chromatin context and G-quadruplexes integrate with transcription factor binding unknown\", \"Transcriptional regulation of KIT in melanocytes and ICC not comparably dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Engineered SCF partial agonists that reduce KIT dimerization efficiency demonstrated that signal amplitude, not just signal quality, determines cell-type-selective biological outcomes — separating hematopoietic expansion from mast cell activation.\",\n      \"evidence\": \"SCF engineering with in vitro dimerization assays, hematopoietic progenitor and mast cell activation assays, and mouse anaphylaxis/hematopoiesis models\",\n      \"pmids\": [\"28283060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for differential sensitivity thresholds in progenitors vs. mast cells unresolved\", \"Clinical translatability of partial agonist approach not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that Gαi1/3 proteins associate with activated KIT to promote its endocytosis and sustain Akt-mTOR/Erk signaling added a heterotrimeric G protein component to KIT signal transduction previously considered exclusively tyrosine-kinase-driven.\",\n      \"evidence\": \"Co-IP, Gαi1/3 siRNA/KO in HUVECs, dominant-negative mutants, and AAV-mediated endothelial knockdown in retinal angiogenesis model\",\n      \"pmids\": [\"37063428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Gαi coupling operates in hematopoietic or mast cell contexts unknown\", \"Structural basis for Gαi–KIT interaction uncharacterized\", \"Role of Gαi in mutant KIT signaling not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length KIT–SCF complex structure at atomic resolution, the E3 ligase responsible for phospho-MITF degradation downstream of KIT, how G-quadruplex structures functionally regulate KIT transcription in vivo, and whether Gαi coupling modulates KIT signaling in the mast cell and hematopoietic contexts where KIT is most physiologically important.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length KIT–SCF ectodomain complex structure\", \"E3 ligase for MITF downstream of KIT unidentified\", \"In vivo functional role of promoter G-quadruplexes not demonstrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 6, 7, 24, 32]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 7, 16, 37]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 6, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 3, 16, 23, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 14, 15, 21, 25, 26, 37, 38]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 4, 9, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 10, 11, 17, 20, 30, 31, 35]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 12]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [28, 33, 34, 36]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KITLG\",\n      \"MITF\",\n      \"PTPN11\",\n      \"GRB2\",\n      \"LYN\",\n      \"STAT3\",\n      \"GNAI1\",\n      \"GNAI3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}